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PATHWAY SEMANTICS:
AN ALGEBRAIC DATA DRIVEN ALGORITHM TO GENERATE HYPOTHESES
ABOUT MOLECULAR PATTERNS UNDERLYING DISEASE PROGRESSION

Mary Frances McGuire, PhD
The University of Texas School of Biomedical Informatics at Houston, 2011
Primary Advisor: M. Sriram Iyengar, PhD
ABSTRACT
The overarching goal of the Pathway Semantics Algorithm (PSA) is to improve the in
silico identification of clinically useful hypotheses about molecular patterns in disease
progression. By framing biomedical questions within a variety of matrix representations,
PSA has the flexibility to analyze combined quantitative and qualitative data over a wide
range of stratifications. The resulting hypothetical answers can then move to in vitro and
in vivo verification, research assay optimization, clinical validation, and
commercialization. Herein PSA is shown to generate novel hypotheses about the
significant biological pathways in two disease domains: shock / trauma and hemophilia
A, and validated experimentally in the latter. The PSA matrix algebra approach identified
differential molecular patterns in biological networks over time and outcome that would
not be easily found through direct assays, literature or database searches.
In this dissertation, Chapter 1 provides a broad overview of the background and
motivation for the study, followed by Chapter 2 with a literature review of relevant
vii

computational methods. Chapters 3 and 4 describe PSA for node and edge analysis
respectively, and apply the method to disease progression in shock / trauma. Chapter 5
demonstrates the application of PSA to hemophilia A and the validation with
experimental results. The work is summarized in Chapter 6, followed by extensive
references and an Appendix with additional material.

Disclaimer: The content is solely the responsibility of the author and does not necessarily
represent the official views of any employer, funding agency or institution.
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Chapter 1 Introduction
Background and Motivation
Clinical diagnosis, prognosis, and therapies for disease progression utilize
established phenotypes and syndrome characterizations identified by the clinician based
on patient data such as demographics, physiological observations over time, lab,
radiology and microscopy reports, and transfusion and drug orders. Recent advances in
the collection and assessment of molecular data offer the opportunity to use this data to
increase understanding of disease progression, and, in the near future, to add this
information to assist clinicians in patient care.
There are two major approaches to molecular pattern discovery. Quantitative
methods produce lists of molecules that differentiate disease states based on biofluid or
tissue analysis. Mass spectrometry is the most common technique for unbiased discovery
where all molecular components within the capability of the equipment and its algorithms
are identified(Rifai, Gillette, & Carr, 2006). Microarray immunoassay techniques are
more sensitive and specific in molecular identification, but they only measure the
concentrations of a predetermined panel of molecules(Jastrow et al., 2009). Both
techniques have benefits and drawbacks for clinical usage, particularly in the analysis of
human serum(Hoofnagle & Wener, 2009). Qualitative methods produce lists of
molecules, molecular interactions, and biological pathways gathered from published
literature and databases; techniques include manual and automated text mining and
network analyses to uncover disease associations(Yang, Adelstein, & Kassis, 2009;
Yang, Pospisil, Iyer, Adelstein, & Kassis, 2008; Yanliang, Yang, & Min, 2009). Factors
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relevant to quality molecular pattern discovery include minimization of restrictions on
initial molecule identification; measurement of biofluids likely to have molecules with
significant sensitivity and specificity to a disease; identification of patterns of molecules
and molecular interactions based on the measured biofluids; use of bioinformatics to
connect identified molecules with published literature and databases; and support of
computationally tractable algorithms for discovery(Good et al., 2007; Lescuyer,
Hochstrasser, & Rabilloud, 2007; Rifai et al., 2006).
Abundance of quantitative molecular data. Rapid advances in lab technologies
have made it easier and cheaper to measure vast quantities of molecular data in human
blood and tissue. For example, multiplex molecular technologies now perform
simultaneous measurements of millions of biological entities within the same assay. Not
only is this faster than single measurements such as blots, performing the assays at the
same time limits the environmental and operational variability that influences assay
interpretation. The general public is now aware of the potential of molecular profiling.
Early adopters can now contact the Biophysical Corporation in Austin, Texas for a
$3,400 “biophysical” assay of more than 250 blood molecules considered to be
“diagnostic biomarkers” associated with diseases or conditions(Biophysical, 2009).
Microarrays are a well-known multiplex technology that has been at the leading edge
of biomedicine since the 1990s. The term microarray was originally used for the
miniature DNA microarrays that measure thousands of specific DNA sequences from
biological samples on glass slide chips or nano-well arrays. DNA microarray technology
has been applied in many areas such as gene expression profiling to find which genes
2

change expression in response to disease and to compare genomes in different
organisms(Khan et al., 1999; Tintle et al., 2008).
Next generation methods are manipulating and creating even more data: Illumina
sequencing technology processes massively parallel sequencing of millions of DNA
fragments(Illumina, 2009). The ability to simultaneously measure proteins, proteinprotein interactions and protein-DNA interactions in tissue and biofluids is increasing.
Multiple expression levels of cytokines – signaling proteins that play important roles in
cell physiology and pathology - can now be simultaneously determined using enzymelinked immunosorbent assay (ELISA)-based protein array technology. High density
protein microarrays can now profile over 8000 proteins(Invitrogen, 2009).
Automated techniques are speeding up the processing of molecular data while
decreasing the expense. Immunohistochemistry (IHC) localizes proteins in cells of tissue
sections to identify molecules associated with cellular pathways and functions. IHC is
used extensively to evaluate cancerous tumors, and has been traditionally scored by
fluorescent in-situ hybridization (FISH), a sensitive but slow, complex and costly
cytogenetic technique. New scoring methods, such as the automated cellular imaging
system ACIS™, are now proving to be faster, less expensive, reliable and as accurate as
FISH(Tawfik et al., 2006).
The technical ability to measure this deluge of quantitative molecular data is now
about to move from the bioscience lab to clinical research for use in personalized
medicine. For example, an integrated blood barcode assay chip is now in development for
bedside use in clinical trials. It measures a large number of serum proteins within a few
3

minutes of a small sample(Fan et al., 2008). The challenge of new technologies is in
understanding the biomedical significance of the huge amount of data generated(Hu,
Coombes, Morris, & Baggerly, 2005; Rogers & Cambrosio, 2007).
Abundance of qualitative pathway knowledge resources. In addition to the
quantitative data now measurable, there is an ever-increasing amount of qualitative data
about molecular interactions. From the mid 1980s through 2008, PubMed gained 30,000
articles on signaling pathways and the advent of microarray technologies in the late
1990s spurred on signaling pathway research. More than 10,000 of the 30,000 PubMed
signaling pathway articles relate to human cancer(NLM, 2008a), 347 articles to trauma,
and 26 to multiple organ failure(NLM, 2008b). The under-representation in the latter two
categories may be due to the fact that cancer studies examine molecular pathways in
excised tissue, whereas trauma studies measure initiator signaling molecules in biofluids
and infer the signaling pathways on an experiment by experiment basis.
Biological researchers, both experimental and theoretical, have organized the
patterns of molecular interactions into spatio-temporal networks of pathways
representative of cellular functions such as regulation of gene expression, metabolism and
signaling(Slonim, 2002). Biological networks include measured molecules and
interactions plus molecules and interactions inferred by computation or by similarities
among organisms such as Saccharomyces cerevisiae, Escherichia coli, Rattus norvegicus,
Mus musculus, and Homo sapiens.
Signal transduction pathways represent the cascades of reactions within or between
cells that mediate cellular processes. They are the primary communication channels
4

within the organism to regulate physiology(Pawson & Nash, 2000) and they are usually
drawn as networks with molecules as nodes and molecular interactions as edges. Once a
network is in graphical form, it can be analyzed using graph theoretical methods from
computer science, matrix algebra, and other mathematical constructs.
Signaling networks are inferred experimentally and / or computationally
(Eungdamrong & Iyengar, 2004) from temporal and spatial patterns of molecules
associated with specific intracellular functions such as apoptosis(Cho, Shin, Lee, &
Wolkenhauer, 2003), gene activation and cell growth(Bhalla & Iyengar, 1999;
Levchenko, 2003) or systemic functions such as inflammatory response(Calvano et al.,
2005; E. Lin, Calvano, & Lowry, 2000; Salomao et al., 2008).
As technology advances, the ever-updated pathway information is disseminated
through the internet, and there are numerous web-based commercial and academic
knowledge bases of biological pathways. In 2001, only 18 pathway websites were
active(Wixon, 2001). Today PathGuide.org references more than 290 pathway resources
categorized by availability, data access methods, tools, organisms, network category, and
contents. More than 30 million molecular interactions are accessible(PathGuide, 2010).
The Pathway Database section of KEGG (Kyoto Encyclopedia of Genes and Genomes)
includes networks relating to metabolism, genetic and environmental information
processing, cellular processes, human diseases and drug development(KEGG, 2009). The
Signal Transduction Knowledge Environment (STKE) lists 49 canonical pathways with
1084 component molecules and 33 specific pathways (specific to a particular organism,
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tissue, or cell type) with 718 components(STKE, 2009). There is an abundance of
accessible resources on biological pathways.
Problem Statement
The general problem is that there has been a dearth of methods that support datadriven, molecular based, clinical research in disease progression. First, patient molecular
data is limited. There are usually few patients in a prospective observational non-cancer
clinical study of disease progression. Measuring molecular patterns in bio-fluids or
tissues is not a standard procedure in clinical care research, even in an Intensive Care
Unit (ICU). This results in small sample sizes of patient data limited to non-parametric
statistical analysis. Secondly, analysis methods for molecular patient data are uncommon,
and time-oriented algorithms are even scarcer, as will be shown in Chapter 2.
The question is how to use the limited temporal molecular patient data to add more
information that is available, but not easily accessible, from biochemical resources in
literature and databases, and then, how to analyze that combined, larger data set over time
and other stratifications to analyze disease progression. The challenge with resources,
such as databases of molecular interactions, is analyzing the spatiotemporal interplay of
uncountable numbers of molecular interactions within each cell and across the 100
trillion (1014) cells in the human body.
The first step would be for research to uncover “gold standards” of molecular
patterns associated with disease progression, followed by development of protocols and
assays for bedside use.

6

The specific problem addressed by this study was how to connect quantitative
spatiotemporal bioassay data of signaling molecules called cytokines with qualitative
biological pathway information in order to uncover likely molecular patterns associated
with systemic responses in disease progression.
Signaling pathways are initiated by biological entities outside the cell and they
control cellular functions including proliferation, apoptosis, and necrosis. Signaling
pathway initiators include cytokines, hormones and growth factors in the blood, lymph or
interstitial tissue and biomechanical stimuli like tissue strain(Knobloch, Madhavan, Nam,
Agarwal, & Agarwal, 2008; Lucitti et al., 2007; Morrow et al., 2007). When signaling
molecules travel through the body and meet matching receptors on a cell, the functions of
the respective signaling pathways in that cell are activated, modulated, or inhibited.
Because the measurable signaling initiators of the pathways appear before the
inferred signaling pathway functions are executed, hypotheses can be generated to
discover what this “advance notice” means – such as what are the underlying biological
mechanisms or how treatment might direct the body system to mitigate pathways that go
out-of-control. For example, initiators of pathway cellular functions can make signaling
pathways compete or cooperate to destroy malformed cells, or suppress that destruction,
resulting in tumors that may be cancerous. In trauma, the initiators activate a proinflammatory systemic response across many pathways to help the body fight immediate
injury; however, if the “turn off” set of signals is not received in time by the pathways in
the cells, the person can die. Since the initiators occur in the body ahead of the response,
and initiating signaling molecules such as cytokines can be measured in serum, there
7

exists an “advance warning system.” Early knowledge of which pathways are active or
inactive over time within a specific biological context can assist clinical decisions. This is
of particular use in trauma where time is of the essence.
Study Purpose, Scope and Deliverables
The purpose of this study was to develop and document a computational method to
support the research hypotheses that cellular functions are the foundation for
physiological mechanisms, and that systemic patterns of measured molecules could be
associated with larger biological pathways amenable to time-based analysis of disease
progression.
The method was named the Pathway Semantics Algorithm (PSA) because it analyzes
the meaning of biological pathways within clinical contexts. PSA addresses the need for a
computationally tractable methodology to connect quantitative molecular data with
qualitative pathways. PSA was designed to support translational systems biology and
enable dimensionality reduction of data, statistically guided pathway selection,
comparison of pathways across clinical conditions and over time via matrix algebra, and
generation of clinical/biological hypotheses for wet lab testing or clinical trials. PSA was
applied to analyze systemic responses in two biomedical domains, and validated through
literature, expert opinion, and experiment.
Study Significance
The capability exists today for generating large amounts of quantitative bioassay data
for patients in a variety of clinical conditions such as critical care and cancer.
Simultaneously, availability of qualitative information on biological pathways is rapidly
8

increasing. However, there is a dearth of methods that can effectively connect these two
categories of data with a view to achieving a deeper understanding of the relationship
between evoked pathways and concentrations of initiating bio-molecules. This
information can yield valuable insights into underlying mechanisms of disease
progression and help formulate therapy.
The Pathway Semantics Algorithm, the subject of this research, is a step in this
integrative direction, following the viewpoint expressed by Simon Rosenfeld of the
National Cancer Institute that the first small steps toward translational systems biology
models “should be in the direction of integration rather than towards further elaboration
of individual processes and their in-depth mathematical modeling. In fact, the mass of the
knowledge currently available is so monstrously huge that it may have already passed the
point of being manageable. There is a serious risk of completely losing this knowledge
for any practical purpose unless decisive steps towards integration are
undertaken.”(Rosenfeld & Kapetanovic, 2008)
In chapter 2, the literature review confirmed that there are a limited number of
computational methods available for translational clinical research. One of the challenges
is the development of new methods based on theoretically sound and computationally
tractable techniques that can be scaled to an organism level.
The potential significance of this study is that it adds a novel methodology called the
Pathway Semantics Algorithm (PSA) that addresses these needs. In contrast to other
graph/matrix systems biology tools, PSA compares networks of patient data-driven
biological pathways over time or other stratifications at the organism level. Temporal
9

analysis is important and the time factor has been recognized as important in the
specificity of signaling pathways(De Meyts et al., 1995). However, time-based pathway
models at the molecular level generally consist of sets of differential equations with
assumed kinetic constants that are computationally intractable at the organism level. PSA
overcomes this limitation.
The methodology appears to be repeatable, generalizable, scalable and extendable.
PSA expands patient data by incorporating biological pathway data into the mix, and then
facilitates analysis of that data over time and other stratifications using numerical linear
algebra to generate useful hypotheses that answer biological questions. PSA algebraically
post-processes evoked pathway networks to reveal changing molecular patterns not easily
observed in the static text and graphical formats output by biological pathway generation
programs such as Ingenuity Pathway Analysis (www.ingenuity.com). The algebraic postprocessing changes the data representation; this is important because the data
representation space is one of the four inter-related problem spaces in scientific
discovery, along with the hypothesis space, the experiment space, and the experimental
paradigm. Changes in data representation uncover regularities and invariants, facilitate
categorization, and suggest alternative search strategies key to scientific
discovery(Schunn & Klahr, 1995).
PSA differs from graphical analysis since it does not start with predetermined graphs
of canonical pathways. PSA starts with clinical data upon which biological pathway
networks are constructed based on most likely interactions even if they are not part of
canonical pathways. Finally, PSA uses mathematical algorithms for matrix representation
10

and computation that are readily available and can be implemented in a wide variety of
software. A key advantage of PSA is that it narrows down the potential hypotheses for
further investigation, thus reducing costly lab and clinical research efforts.
PSA can benefit clinical practice because it shows how the fundamental mathematics
of numerical linear algebra can be used in a novel manner for comparative analysis of
biological pathways in disease progression. Simple computations can be performed using
spreadsheet calculations familiar to clinicians; more complex work for specific clinical
contexts can be developed into software. Finally, PSA can benefit future research because
it is a fundamental method that is adaptable to a wide range of studies on disease
progression or comparison.
Theoretical / conceptual framework
The theoretical substruction map(Dulock & Holzemer, 1991; Hinshaw, 1979;
McQuiston & Campbell, 1997; Trego, 2009; Wolf & Heinzer, 1999) for the research
project is given in the Appendix, illustrating the linkages from the source study fields
used through to the data analysis performed. The framework is as follows.
Study fields. The project draws on work in the fields of systems biology and clinical
research.
Theories. From systems biology come theories of molecular interactions and
algebraic analysis of networks. From clinical research come theories of disease
progression.
Models. Models used include network representation of biological interactions,
matrix representation of a network, and models of inflammatory and immune response.
11

Concepts. The major concepts included are molecular interactions, directed graphs,
molecules, matrix algebra, changing patterns of molecules over time, and measures of
disease progression.
Aims. The specific aims of the project were to:
•

develop the PSA method for node analysis and edge analysis,

•

apply PSA to a study of multiple organ failure in shock / trauma and to a study of
immune response in hemophilia A, and

•

validate PSA through literature search, expert opinion, and, if feasible, laboratory
experiment.

Research questions. The research questions for each application were:
•

Which molecules differentiate disease progression?

•

Which molecular interactions differentiate disease progression?

Variables. Variables included measured molecules, inferred molecules, inferred
molecular interactions, time, clinical outcomes or treatment effects.
Operational definitions.
•

Measured molecules: cytokines

•

Inferred molecules: genes, proteins, chemicals

•

Inferred molecular interactions: molecule to molecule interactions

•

Time: time in periods of hours or elapsed time in days

•

Outcome: multiple organ failure or not

•

Treatment effect: PBS versus CFA/I

12

Data analysis. Cytokines were measured in pg/ml. Inferred molecules and molecular
interactions were obtained from a pathway database based on the cytokine measures.
Time was measured in hours or days. The analysis was done on the stratification of
outcome or treatment effect.
Summary
To date there appears to be no generalizible, computable systems-level methods that
utilize spatiotemporal bioassay data to answer biomedical questions arising from
comparative analysis of biological pathways. However, there is a need to connect
bioassay data with pathway information within specific biomedical contexts and to
facilitate comparison of biological pathways by time, outcome, molecular location and/or
cell cycle phase. If these needs could be met, clinical research could start utilizing the
wealth of constantly updated biological pathway information on a regular basis, and
generate baseline hypotheses for mechanisms and recommended therapy – and keep a
few steps ahead of the molecular data deluge that is about to impact clinical medicine.
The overarching goal of the Pathway Semantics Algorithm is to improve the in silico
identification of clinically useful hypotheses about molecular patterns in disease
progression. By framing biomedical questions within a variety of matrix representations,
PSA has the flexibility to analyze combined quantitative and qualitative data over a wide
range of stratifications. The resulting hypothetical answers can then move to in vitro and
in vivo verification, research assay optimization, clinical validation, and
commercialization. Herein PSA is shown to generate novel hypotheses about the
significant biological pathways in two disease domains: shock / trauma and hemophilia
13

A, and validated experimentally in the latter. The PSA matrix algebra approach identified
differential molecular patterns in biological networks over time and outcome that would
not be easily found through direct assays, literature or database searches.
The next chapter is a literature review of relevant computational methods. Chapters 3
and 4 describe PSA for node and edge analysis respectively, and apply the method to
disease progression in shock / trauma. Chapter 5 demonstrates the application of PSA to
hemophilia A and the validation with experimental results. The work is summarized in
Chapter 6, followed by extensive references and an Appendix with additional material.
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Chapter 2 Literature Survey
This chapter presents a survey of computational tools, techniques, and resources
from systems biology that can be used to increase understanding of the physiological
mechanisms in disease progression. The intention is to show data processing and analysis
methods that may be adaptable from the molecular and cellular levels to investigations at
the tissue, organ, and whole body system levels, highlighting common processes and
procedures that may be useful for investigative studies and personalized medicine. The
scope of this chapter is limited to resources for potential applications in shock trauma and
critical care; however, the underlying methods may be useful in a wide range of
translational clinical research in disease progression.
It is my contention that systems methods can assist in the identification of
measurable characteristics in critically injured trauma patients that point to underlying
disrupted biological mechanisms that may be amenable to treatment with a resultant
increase in survival(Karvunidis, Mares, Thongboonkerd, & Matejovic, 2009; Neugebauer
& Tjardes, 2004; Polpitiya, McDunn, Burykin, Ghosh, & Cobb, 2009; Vodovotz, Csete,
Bartels, Chang, & An, 2008). The challenge is that systems biology analyzes physiology
from the “bottom-up”, modeling molecules, organelles, and biological pathways within
cells whereas clinical medicine treats a patient from the “top-down”, evaluating the
whole body, based on observable measures from biofluids, tissues, and organs. The data
from both extremes vary considerably over scales of time and space. For example, data
can be baseline, measured at specific intervals, or measured continuously. Data can be
numbers, words or patterns describing serum protein concentrations or heart rates.
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There are vast databases with biochemical data and computational models that can
offer insights into disease progression, if they can be linked to specific patterns of patient
characteristics and if clinicians were enabled to judge clinically relevant factors that arose
from systems biology. Specific treatments based on an individual’s underlying
physiology, in addition to phenotype(Butte, 2008; Hofer et al., 2009; Salluh & Bozza,
2008), are important in the development of personalized therapies. Clearly a two-stage
translational approach is required: first, clinical researchers need to identify “gold
standard” data patterns that include measurable biochemical data associated with
prognosis, diagnosis or treatment. Secondly, protocols and parameters that incorporate
this information must be developed for clinical use. In both stages, computational
methods are needed: first for discovery of likely biochemical patterns and disease
associations, and secondly, to provide patient data-driven reports that include systems
information to assist clinicians in assessing and directing patient care.
Because ICUs are already prepared to monitor and collect massive amounts of
temporal physiological and clinical data, they are a likely candidate location for studies
and applications of translational systems biology. In this chapter, I present a selection of
recent approaches and their application to research in biological processes in trauma and
critical care, such as inflammatory, immune and injury responses. The emphasis is on
computational methods that can be used for data-driven systems analysis of disease
progression.
In the following section, I give a short overview of systems analysis and systems
biology, approaches used in trauma research, and data available. In Section 3
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computational methods are discussed, followed by Section 4 with selected applications.
The literature review is summarized in Section 5.
Systems Analysis and Systems Biology
Systems analysis is “a method of describing and understanding complex interactions
among large numbers of processes or components in a generalized way. The focus is on
identifying the fundamental units of a system and defining how they interact rather than
the internal processes of each unit”(Aber & Melillo, 2001; Yourdon, 1988). Systems
analysis can be performed to generate or test hypotheses about the systems behavior
within specific assumptions and constraints. Analysis techniques may be qualitative or
quantitative, static or dynamic, stochastic or deterministic, or combinations. The
fundamental units (components or processes) may be nested within a hierarchy or
overlapping.
Systems biology, a subcategory of computational biology, is defined by the National
Library of Medicine (NLM) as the “comprehensive, methodical analysis of complex
biological systems by monitoring responses to perturbations of biological processes and
using the large scale, computerized collection and analysis of the data to develop and test
models of biological systems”(NLM, 2009). From its beginnings, systems biology aimed
at building mathematical frameworks with some predictive abilities based on systematic
organization of genomic and proteomic data(Aggarwal & Lee, 2003). Since then, the
scope of systems biology has expanded and spawned a number of related offshoots such
as translational research(NIH, 2009), translational systems biology(G. An, Faeder, &
Vodovotz, 2008), translational bioinformatics(AMIA, 2006), and systems
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medicine(Clermont, Auffray, Moreau, Rocke, Delavi et al., 2009; Clermont, Auffray,
Moreau, Rocke, Dalevi et al., 2009). Although analysis goals, abstraction levels, and
scales vary widely, the fundamental units under study are usually molecules, cells,
tissues, organs, and organisms within a hierarchical framework with modular control
elements or related biological processes(G. C. An, 2010; M S Iyengar, Brown, &
McGuire, 2007; Lauffenburger, 2000; Malhotra et al., 2008).
Systems approaches in trauma
Trauma refers to serious bodily injury, which, if of sufficient magnitude, may be
accompanied by initiation of the systemic inflammatory response. Causes of trauma
include penetrating injuries from gunshots and stab wounds, blunt injuries, such as those
sustained during automotive accidents, and burns. In addition to direct tissue damage,
trauma can result in injury to remote organs due to disruptions in normal physiology and
underlying protective biological mechanisms. These remote injuries can be rapid in onset
and potentially fatal if allowed to proceed unabated. Moreover, trauma is the leading
cause of mortality in the US among individuals under 45 years of age, and the cause of
death for 74% of all deaths for people ages 15-24(Heron, Hoyert, Xu, Scott, & TejadaVera, 2008). In critically ill patients, normal biological processes are disrupted but the
associated pathophysiology is incompletely understood(Deitch, 1992; Maier et al., 2007;
Wan et al., 2008).
Within the past decade, a number of systems approaches for analysis of trauma and
critical illness have been developed(Buchman, 2009; Vodovotz et al., 2007).
Computational methods have been used to increase understanding of systemic functions
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such as inflammation and immune response(G. An, 2001; Dong, Foteinou, Calvano,
Lowry, & Androulakis, 2010; N. Y. Li et al., 2008; Ta'asan & Gandlin, 2009; Vasilescu,
Buttenschoen, Olteanu, & Flondor, 2007; Vodovotz et al., 2009)and the effects of drug
dosing(Yamamura et al., 2004), as well as organ specific issues such as heart rate
complexity(Cancio et al., 2008; Riordan, Norris, Jenkins, & Morris, 2009)and acute lung
injury(Ware et al., 2009). Multiscale computational models of angiogenesis, from the
molecular to the organ system levels, have been integrated to improve predictive
capabilities(Qutub, Mac Gabhann, Karagiannis, Vempati, & Popel, 2009). At the
molecular/cellular systems level, there are numerous computational approaches in
systems biology used to study biological mechanisms such as signaling(Rangamani &
Iyengar, 2008), metabolism(Palsson, Joshi, & Ozturk, 1987), and protein interactions(C.
Y. Lin et al., 2008)that underlie disease progression. With the advent of new technologies
that make it feasible – and soon cost-effective – to capture patient’s molecular data such
as mRNA expression or serum protein concentrations, translational clinical research can
benefit from using computational approaches beyond classical statistical inference. A
systems-wide analysis of data from the molecular to the organism level can help design
evidence-based personalized therapies.
Data for systems approaches in trauma
The complex and often rapid progressions of shock trauma and critical illness
provide a vast quantity of patient data that can be collected and evaluated through realtime monitoring in an intensive care unit (ICU) on a continuous, hourly, or daily basis.
Intensive care units collect one item of documented clinical information per patient each
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minute(Manor-Shulman, Beyene, Frndova, & Parshuram, 2008). In addition to monitored
data, patient data includes transfusion and drug orders, microscopy, radiology and
laboratory reports, nursing and clinician notes, and patient demographics. As bedside
biofluid measurement devices move from prototype to practicality(Fan et al., 2008;
Sorger, 2008), a patient’s molecular data such as serum proteins can also be collected in
time to be of use in the ICU; currently, turnaround time for molecular assays is not
practical for other than research use. The challenge today is to understand the meaning of
all this data in terms of disease progression, and develop data-driven protocols that will
be in place when the technology is available. For example, research has shown that
specific patterns of cytokine molecules over time are associated with trauma
progression(Jastrow et al., 2009; Maier et al., 2007; Roumen et al., 1993). Cascade
patterns of molecular interactions, such as those triggered by cytokines, have been
identified as biological pathways – spatiotemporal networks representative of cellular
functions that regulate gene expression, metabolism and signaling(Slonim, 2002).
Because cytokines drive signaling in biological pathways, adding cytokine data may
provide insight into the underlying biological mechanisms.
There are an ever-increasing number of databases with information about biological
pathways. In 2001, only 18 pathway websites were active(Wixon, 2001). Today,
PathGuide.org references more than 290 pathway resources categorized by availability,
data access methods, tools, organisms, network category, and contents. More than 30
million molecular interactions are accessible via the Internet(PathGuide, 2010). The
Pathway Database section of KEGG (Kyoto Encyclopedia of Genes and Genomes)
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includes networks relating to metabolism, genetic and environmental information
processing, cellular processes, human diseases and drug development(KEGG, 2009).
More than 1400 curated, experimentally determined, metabolic pathways and enzyme
data for microbial, plant, and vertebrate metabolism are available from the freely
accessible MetaCyc database(Caspi et al., 2010). There are commercial and publicly
available databases of molecular interactions(Tarcea et al., 2009), biological
pathways(Elliott et al., 2008; Visvanathan et al., 2008; Wixon, 2001), and genomic
correlates(L. T. Sam et al., 2009). The Signal Transduction Knowledge Environment
(STKE) lists 49 canonical pathways with 1084 component molecules and 33 pathways
specific to a particular organism, tissue, or cell type with 718 components(STKE, 2009).
PubMed lists more than 250,000 articles with content about signal transduction pathways;
the earliest articles are from 1947 – before systems biology as such existed(Baumgardt,
1947; Berliner, 1947; Monnier & Boehm, 1947).
The question is how to integrate all this data? One approach is to use computational
methods from systems biology to connect patient data with data from basic science
resources in biology, chemistry and physics to develop research models that can
transition to data-driven clinical practice. See Figure 2-1. Even with computational
approaches, the data translations and transformations among levels from molecule to
organism and vice-versa are far from seamless. Most applications cobble together several
methods to achieve their research goals. In the next section, I review some of the major
computational methods that have been used to analyze biological processes related to
trauma and critical illness; this is followed by Section 4, giving details of several
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applications. The intent is to inspire creative use of methods and data in the investigation
of trauma and critical illness, with the goal of improving patient care.

Systems Biology
Resources

Patient Data

Computational
Methods

Diagnosis, Prognosis,
and Treatment of
Disease Progression

Hypotheses about
Disease Progression

Figure 2-1 Computational methods integrate translational research

Computational Methods
The biological processes in shock trauma and critical illness are complex and
unstable. There are simultaneous and rapid changes of biological pathways across and
within the entire body. Extracellular and intracellular signaling modulates systems-wide
mechanisms such as inflammatory response(Levi, Keller, Van Gorp, & Ten Cate, 2003;
Pillay, Hietbrink, Koenderman, & Leenen, 2007; Rezende-Neto et al., 2002), sepsis,
hemorrhagic shock, and resuscitation from hemorrhagic shock(Rittirsch, Flierl, & Ward,
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2008; Tracey, 2007; Webster & Galley, 2009). The choice of systems analysis and
computational methods depends on several factors:
• The systems level(s) under study, from molecule to organism;
• The available data; and
• Which biological processes are under study, within what context, and for
what goals.
Hypotheses about disease progression can be generated computationally in many
ways: from data-driven model-free discovery to the perturbation of in silico models of
biological processes. This section is an overview of common computational methods in
use plus some general considerations for data; selected applications related to trauma and
critical care will be shown in Section 4. Here I first present basic probabilistic and
deterministic approaches that utilize a wide variety of fundamental tools and techniques
that can be used individually, combined, or in combination with other methods. This is
followed by a selection of more specialized methods.
Basic probabilistic approaches
Classical Statistical Inference incorporates no prior information and assumes
independent variables; the approach is used at all systems levels and underlies the
primary tools, such as Student’s t test, used for static analysis of injury response where
there is sufficient data. In contrast, Bayesian Statistical Inference incorporates prior
information and handles interdependent variables. The Bayesian “conditional
probability” approach is becoming more and more widely used in genetic data
analysis(Beaumont & Rannala, 2004), clinical research(Moyé, 2008) and diagnostic
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medicine; complex Bayesian analyses are usually performed using Markov Chain Monte
Carlo (MCMC) computational methods(Broemeling, 2007). MCMC methods use Monte
Carlo random sampling to produce a Markov Chain with state transitions that converge to
an invariant distribution. A Markov Chain is the simplest autonomous form of a discretetime probabilistic state-transition Markov model where the system state is observable.
Common statistical software includes R (www.r-project.org), Spotfire S+
(http://spotfire.tibco.com/products/s-plus/statistical-analysis-software.aspx), SPSS
(www.spss.com), and SAS (www.sas.com). OpenBUGS is open-source software for
Bayesian analysis using MCMC methods (www.openbugs.info/w).
Basic deterministic approaches
Deterministic approaches depend on initial states and chosen parameters. Differential
equations are the primary methods of deterministic dynamic analysis, and are mostly
used at the molecular and cellular levels because they are computationally intensive at
higher levels. For example, modeling one NFκB signaling pathway in one cell activated
by one signaling TNF-α molecule requires 18 nonlinear differential equations, with 33
independent variables and 16 dependent variables in a simplified reaction kinetics
model(Cho et al., 2003); scaling this method directly to the organism level is
computationally intractable. Ordinary differential equations (ODEs) model dynamic
changes in items, such as protein concentrations, over one independent variable whereas
partial differential equations model simultaneous changes over two or more independent
variables. Explicit equations are used, usually with equilibria or other constraint
assumptions. In addition to experimental data, the equations require data for estimated
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biochemical kinetic parameters, which are usually inferred from published results.
Differential equations can be solved using standard mathematical software available as
open source or commercial software such as MATLAB(MathWorks, 2010) and
Mathematica(Wolfram, 2010).
Matrix algebra can be applied from molecular to organism levels. Stoichiometric
matrices are used for flux-balance analysis (FBA) of metabolic biochemical reaction
networks(Palsson et al., 1987; Schilling & Palsson, 1998) to stochastically simulate
chemical kinetics. Unlike differential equation approaches, FBA does not require reaction
rate kinetic parameters or metabolite concentration data. Instead, the key assumptions are
that the system is homeostatic with a balanced system of energy production and
consumption and that the metabolites are “well stirred” so that Gillespie’s Algorithm can
be used(Gillespie, 2008). This steady-state approximation of cellular dynamics can offer
insights into multiscale snapshots of disease progression. Matrix algebra formalisms have
been used to study signaling and regulatory pathways using extreme pathway analysis, an
adaptation of the stoichiometric approach used for metabolic analysis(Gianchandani,
Papin, Price, Joyce, & Palsson, 2006; Papin & Palsson, 2004) and to generate signaling
networks from sparse time series of observed data(Allen et al., 2007). The latter
computational algebra approach has potential for analysis of signaling pathways in
disease progression.
Matrix decomposition methods are the basis for a wide variety of factor and
component analyses in data mining and graphical analyses(Skillicorn, 2007; Sun, Xie,
Zhang, & Faloutsos, 2008). In addition to techniques such as singular value
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decomposition (SVD), new matrix approaches are evolving such as the graphdecorrelation algorthm (GraDe) that performs detailed temporal analyses on large-scale
biological data using knowledge-based matrix factorization. In a recent time-course
microarray experiment of mouse hepatocytes, GraDe provided a detailed separation of
the time-dependent responses to IL-6 stimulation compared to standard
methods(Kowarsch et al., 2010).
Matrix algebra can be performed using software as simple as spreadsheets; more
complex calculations use software such as MATLAB or Mathematica. Code for
Gillespie’s Algorithm is available for R (http://cran.rproject.org/web/packages/GillespieSSA/index.html) and for
Mathematica(http://demonstrations.wolfram.com/DeterministicVersusStochasticChemica
lKinetics/).
Graphical approaches
Cascades of molecular interactions can be represented as directed graphs in order to
use computational methods from graph theory to explore pathways within the graph. The
analysis is usually at the molecular and cellular levels, although the methods can be
adapted for higher levels. Biological pathways can be abstracted as network graphs with
nodes representing molecules and edges being molecular interactions(Alon, 2007;
Ma'ayan, 2008). Patterns of molecules, such as serum cytokines, have been associated
with disease progression in trauma, and graph theory methods offer ways to analyze this
data. Graph theory is supported by extensive computational methods from mathematics
and computer science that are used for analysis of static and dynamic systems ranging
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from computer systems to social networks. Structural properties of the graph can be
measured in many ways such as counting the number of nodes and edges, number of
edges per node or nodes per edge, identifying primary hubs and sub-network motifs.
Computational methods are usually analysis specific. For example, the web-based Hub
Objects Analyzer (Hubba-Hubba, http://hub.iis.sinica.edu.tw/Hubba/index.php) identifies
essential hubs in a protein interaction network by using a combination of software
including databases, graph generators, and topology calculators(C. Y. Lin et al., 2008).
A Bayesian network is a probabilistic graphical model constructed as a directed
acyclic graph (DAG) with nodes representing variables and edges representing the
conditional dependencies between the nodes. Bayesian networks are used for process
modeling and diagnostic reasoning(Darwiche, 2009; Koller & Friedman, 2009). One
class of Bayesian networks is based on Hidden Markov Models (HMMs) - Markov
Chains with hidden rather than visible states but with visible state-dependent outputs.
HMMs can be used to uncover an optimal sequence of state transitions. One limitation of
Bayesian networks is that they must satisfy the local Markov property - each node is
conditionally independent of its non-descendents(Russell & Norvig, 2009); as a result,
graphs with cycles are not supported. This limits modeling of biological pathways to
small sections without loops. Recently, an extension to Bayesian network models, called
Generalized Bayesian Networks (GBN), has been proposed that can model cyclic
networks for use in translational systems biology(Sachs, Itani et al., 2009). There are a
number of software packages for Bayesian networks including the Python library Pebl
(http://code.google.com/p/pebl-project/) and Hugin (www.hugin.com).
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Petri Net methods have been used to analyze Bayesian networks where the nodes are
molecules and the edges represent the dependencies of the interactions between the
nodes. Petri nets perform qualitative, stochastic and continuous analysis of small
biochemical networks by modeling token-based transitions, such as reactions, between
“places” such as proteins. Dynamic modeling is performed by incorporating differential
equations to assign rate functions to transitions(Heiner, Donaldson, & Gilbert, 2010 ).
Petri Net Toolboxes are available for MATLAB and Mathematica, and systems biologyoriented Petri Net software called Snoopy is freely available (http://wwwdssz.informatik.tu-cottbus.de/snoopy.html; www.informatik.unihamburg.de/TGI/PetriNets).
Finally, Spectral Graph Theory incorporates both graph theory and matrix algebra to
examine a network in terms of the eigenvalues and eigenvectors (spectrum) of the
adjacency matrix mapped from the network graph(Cvetković, Doob, Sachs, & Torgasev,
1988). This method has been used to compare basic metabolic networks at the systems
level in three organisms Mycobacterium tuberculosis, Mycobacterium leprae and
Escherichia coli. The results found that the most highly connected biochemical reactions
in an organism are not necessarily those most central to the organism’s metabolism,
suggesting that hubs present in mycobacterial networks that are absent in the human
metabolome may be potential drug targets(Verkhedkar, Raman, Chandra, &
Vishveshwara, 2007).
Pathway databases use graph theory with published biological pathway data and
proprietary computational network analysis algorithms to generate specific biological
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pathways. For example, Biobase (BIOBASE GmbH, Germany; www.biobaseinternational.com) has a data analysis system called ExPlain, and the Ingenuity
Knowledge Base (Ingenuity Systems, US; www.ingenuity.com) supports Ingenuity
Pathway Analysis. Advantages of these combined database / algorithm systems are that
the pathway / molecular interaction data are kept up-to-date, and that the algorithm is
specifically designed to work well with the database to uncover the pathways associated
with the input data. Although this is advantageous for the general user, it must be noted
that the underlying computational methods are not amenable to modification because
they are usually based on proprietary algorithms with limited documentation. In addition,
access to commercial web-based pathway databases and their analysis software is by paid
subscription.
Symbolic approaches
Symbolic logic is a formal qualitative modeling approach used to answer questions at
various levels of abstraction. The questions usually focus on a specific intracellular
function such as signaling and a model is created based on system states and rules for
state changes. Symbolic models can be analyzed or run as simulations; models can be
formally checked and verified. A wide variety of computational methods for symbolic
systems biology have been developed(M. S. Iyengar, 2010 ). There are several
implementations of rule-based modeling for signaling networks(Hlavacek et al., 2006)
such as Pathway Logic, a symbolic rewriting logic based on pi-calculus(Knapp et al.,
2005; Talcott, 2006).
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Artificial Neural Networks (ANN) and Agent-Based Models (ABM)
ANN and ABM methods are used with organism-level data. However, both are
computationally intensive and may require specialized software along with
multiprocessor hardware. The artificial neural network (ANN) is a computational method
to uncover nonlinear patterns based on input data. Several ANN models are generated
from the training input data, and the one with the best fit between predicted and observed
values is considered the optimal ANN model to be used for the actual data and
predictions. Optimization techniques, such as the conjugate gradient decent
method(Fletcher, 2000; Mary F. McGuire & Wolfe, 1973), may be used to optimize the
model. Nonlinear ANN modeling has been shown to be comparable to linear logistic
regression analyses when sample size is adequate. However, it has been shown that
training sets for ANN need at least 800 observations to generate an adequate model – a
sample size not usually found in ICU trauma / critical care studies(Clermont, Angus,
DiRusso, Griffin, & Linde-Zwirble, 2001). Standard mathematical and statistical
software including MATLAB, Mathematica, SPSS and SAS have built-in algorithms or
add-on modules for neural network analysis and optimization.
Agent based simulation consists of an agent-based model (ABM) composed of
autonomous fundamental units, or agents, defined at multiple scales or levels within a
system and the rules that govern the state change interactions among them. The rules may
be deterministic or stochastic. No explicit equations are used and there are no equilibria
assumptions as in most models. The goal is to predict patterns of emergent behaviors that
arise in complex systems from simple rules(G. C. An, 2010). The model must be verified
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and validated in some way; simulations must be run many times to uncover relevant
patterns. Two open-source software packages for ABM development are
NetLogo(Wilensky, 2010)and SeSAm(Würzburg, 2010 ). FLAME (Flexible Large-Scale
Agent Modelling Environment, www.flame.ac.uk)(Coakley, 2007; Richmond, Walker,
Coakley, & Romano, 2010) is a formal framework that allows a wide range of agent and
non-agent models to work together within one simulation environment.
Applications
In this section, I describe computational approaches currently used, or that have the
potential for use, in critical care and trauma-related research. The applications are
organized by research goals at levels from the organism level down to the
cellular/molecular level. A short paragraph summarizes the goal, processes and context
for the example, followed by a list of the methods and data used. See Figure 2-2.
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Apoptosis
Model-Breakpoint Analysis
Petri Nets
Wound Healing
Virtual Epidermis Model
Agent Based Model
Disease States
Generalized Bayesian
Networks

Inflammatory Response
Agent Based Model
Differential Equations

Molecule Cell Tissue Organ

Organism

Mortality Predictors
Probabilistic Models
Artificial Neural Networks

Heart Rate Complexity
Entropy Measures

Traumatic Brain Injury
Equation Based Models

Figure 2-2 Computational analysis at different levels within an organism
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Organism level
The organism level includes research performed at the molecular or cellular levels
that investigates systemic processes such as inflammation, immune and injury responses.
In the next two subsections, I show example of process models and predictive models.
Organism level: Process models
The inflammatory process is a normal physiological response in acute and chronic
disease, and part of the immune response to infection. However, despite numerous
computational models, much work still needs to be done to automate integration of these
models with data across system levels with software usable by nonmathematicians(Vodovotz et al., 2009).
Abstraction. One of the earliest agent based models was developed by An(G. An,
2001) to create a simple abstraction to simulate the nonlinear behavior and dynamic
structure of the inflammatory response. Although the model was based at the cellular
level, the abstraction was used for inference of the systemic response at the organism
level.
•

Method: Agent Based Model using StarLogo software. (StarLogo is now
available as open source OpenStarLogo at http://education.mit.edu/starlogo/)

•

Data: Abstractions of three cell types used as agents: endothelial cells (with injury
states), neutrophils, and circulating mononuclear cells, plus rules for agent
interactions.

Challenge / Response. Endotoxin (LPS) and other challenges have long been used
in shock trauma research(Foteinou, Calvano, Lowry, & Androulakis, 2008; Waage,
33

Brandtzaeg, Halstensen, Kierulf, & Espevik, 1989; Webster & Galley, 2009) to probe
challenge/response relationships.
Dong(Dong et al., 2010) created an agent based simulation to model the host
response to endotoxin using the molecular interactions involved in the NFκB signaling
pathway, coupled with the spatial orientation of various inflammation specific molecules
and cell populations such as macrophages and T-helper cells.
•

Method: Agent Based Model using NetLogo software
(http://ccl.northwestern.edu/netlogo/)

•

Data: Gene expression data from human subjects injected with endotoxin or a
placebo. Biological data for agents (macrophages, cells and molecules) and agent
rules (interaction behavior and rates).

In contrast, Vasilescu(Vasilescu et al., 2007) developed an equation based model to
evaluate whether endotoxin (LPS) tolerance is a component of the immune dysregulation
in patients with trauma, severe acute pancreatitis, and diffuse peritonitis.
•

Method: Differential equations

•

Data: Endotoxin levels, TNF-α plasma levels, and TNF-α releasing capacity of
the whole blood in patients with severe acute pancreatitis, diffuse peritonitis, and
trauma.

Muller(Muller & Tjardes, 2003) found bistability in the early inflammatory response
by using an in vitro model of IL-1 challenge to derive an equation based in vivo model.
The in vitro model was first developed by challenging endothelial cells with IL-1; then,
the expected value of IL-6 at a specific time under a specific challenge was derived. The
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basic mechanism of the in vitro model was expanded to a whole animal IL-1 challenge
that modeled in vivo multistate inflammatory response. Of interest was the outcome that a
small challenge did not lead to a response; however, a challenge above a certain threshold
completely activated the endothelial cells.
•

Method: Differential equations

•

Data: IL-1 challenge levels and resulting IL-6 production levels in endothelial
cells over time scales of minutes, hours and days.

Guthke(Guthke, Moller, Hoffmann, Thies, & Topfer, 2005) generated plausible
models of the gene regulatory networks involved in the human peripheral blood
mononuclear cells’ immune response to an Escherichia coli infection challenge. The
immune interaction networks were reconstructed by reverse engineering. First, a
statistical cluster analysis of the scaled time profiles of the gene expression data was
performed using the fuzzy C-means (FCM) algorithm(Bezdek, Keller, Krisnapuram, &
Pal, 2005), and then expression profiles of the representative genes were used to drive
three dynamic models of gene regulatory networks based on linear differential equations,
systems of linear algebraic equations, or heuristic search strategies.
•

Method: Statistics, differential equations, linear algebra, heuristic search

•

Data: Log-ratios of the expression intensities of more than 18,000 genes in
peripheral blood mononuclear cells at five time points before and after infection
by heat-killed pathogenic Escherichia coli.
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Organism level: Predictive models
Probabilistic methods are used extensively in clinical research. Among the more
common algorithms are the parametric Student’s t test for normally distributed
quantitative variables, the non-parametric Mann-Whitney test for quantitative variables
without a normal distribution, and chi-square tests for qualitative variables. For example,
these methods were used by Pidcoke(Pidcoke et al., 2007) to demonstrate that the diurnal
patterns of blood glucose and insulin requirements in burn ICU patients are similar to
those in healthy subjects.
•

Method: Means, frequency analysis, simple and cosine regressions, Student’s t
test, Mann-Whitney test, chi-square test

•

Data: From 156 burn patients: total body surface area burned, injury severity
score, polytrauma, age, gender, inhalation injury, glucose level (hourly), insulin
dose (hourly), outcomes.

Cohen(Cohen et al., 2010) used hierarchical clustering to identify patterns of
patients’ changing physiological states that were predictive of infection, multiple organ
failure and mortality. Clustering is a multidimensional analysis that identifies groups of
similar variables, with the results displayed as a dendogram tree structure. Limitations are
that a variable may belong to only one cluster group, and the number of clusters may
influence the result.
•

Method: Hierarchical clustering, linear discriminant analysis, correlations

•

Data: 45 measures of physiological, clinical, and treatment data were collected
every minute from each of 17 severely injured trauma patients. Data for the
36

cluster analysis: continuous heart monitor, ventilator, and microdialysis data over
24–72 hours (52,000 data points).
Using a classical statistical model, Ware(Ware et al., 2009) identified a combination
of biologic and clinical markers in patient data that predicted acute lung injury and acute
respiratory distress syndrome.
•

Method: Wilcoxon rank sum test for continuous variables. Fisher’s exact test for
categorical variables. Spearman rank correlation coefficient. Receiver Operator
Curves (ROCs). Odds ratios.

•

Data: Retrospective study from NHLBI ARDS randomized controlled trial:
patient baseline plasma measures of IL-6, IL-8, TNFR1, von Willebrand factor,
surfactant protein D, sICAM-1, PAI-1, protein C plus baseline clinical variables
such as age, cause of ALI/ARDS and APACHE III scores.

In contrast, Peelen(Peelen et al., 2010) constructed three Markov models based on
clinical data to gain insights into the probabilistic state transitions in organ failure
progression in successive days of ICU stay. Peelen’s models identified potential clinical
patient states (number and type of failing organ systems) along with the probabilities that
each state would be followed by another state, or persist over time.
•

Method: Markov models with dimensionality reduction via additive logistic
regression; implementation by hierarchical dynamic Bayesian networks; followed
by stochastic simulations.
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•

Data: Temporal clinical data from a prospective study of severe sepsis patients.
Patient data included SOFA scores per each of six organ systems plus total SOFA
scores.

Artificial neural networks (ANNs) were constructed by Yamamura(Yamamura et al.,
2004) to predict the plasma concentration of Arbekacin sulfate, an aminoglycoside, in
burn patients and, from that prediction, identify patients whose Arbekacin sulfate
antibiotic would be sub-therapeutic based on the patients’ physiological data. ANN
results were superior to multivariate logistic regression analysis in classifying patients’
outcomes.
•

Method: Three-layered ANN model (Statistica software, www.statsoft.com).
Conjugate gradient decent method for optimization during ANN training with
training data. Leave-one-out cross-validation of predictive performance with test
data. Multivariate logistic regression analysis (SPSS, JMP(SAS) and Statistica
software).

•

Data: Clinical physiological data from 30 burn patients, plus data for assessing
burn severity. Training data for ANN model: dose, body mass index (BMI),
parenteral fluid, creatinine concentration and burn severity parameters.
Organ level

Heart. Using Multiscale Entropy (MSE) to assess Heart Rate Complexity (HRC),
Riordan(Riordan et al., 2009) found that early loss of HRC was predictive of mortality
regardless of anatomic location, severity or mechanism of injury.
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•

Method: HRC assessed by Multiscale Entropy (MSE)(Costa, Goldberger, & Peng,
2005). Statistics (R software): Fisher’s exact test, Wilcoxon’s Rank Sum test,
Kruskal-Wallis test, logistic regression, odds ratios, Receiver Operator Curves
(ROCs).

•

Data: MSE; continuous physiological data from the first available 6 hours plus
clinical data and demographics from 2718 trauma patients.

Although HRC seems to be a useful mortality predictor in trauma, most HRC
measures require a traditional 800-beat data set. In an emergency situation, such as a
battlefield, this large amount of data presents a monitoring challenge. Using three entropy
measures with data sets as small as 100 beats to assess HRC, Batchinsky(Batchinsky et
al., 2009) found that HRC was decreased in pre-hospital trauma patients who died.
•

Method: HRC assessed by approximate entropy, sample entropy and similarity of
distributions. Statistics (SAS): Student’s t test, Mann-Whitney U test, logistic
regression, Receiver Operator Curves (ROCs), odds ratios, maximum likelihood,
Pearson chi-square.

•

Data: EKGs with 800 RRIs from 31 pre-hospital trauma patients, with data sets
sampled at 800, 600, 400, 200, and 100-beat data sets.

Brain. Numerous computational models have been developed to increase
understanding of traumatic brain injury resulting from blast survivability in war zones
with the goal of improving design of personal protective equipment. Moore(D. F. Moore
et al., 2009) used equation based models to study the effects of primary blasts on the
central nervous system, and found that blast waves directly propagate into the brain and
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that stresses develop in central nervous system tissues comparable to those significant in
mTBI or concussive injuries in sports.
•

Method: Blast-solid interaction simulation of a full head mesh, with mesh
generated from nonlinear partial differential equations in computational fluid
mechanics software (ICEMCFD, www.ansys.com/products/icemcfd-meshgen.asp) and brain tissue modeled by nonlinear algebraic equations of state.

•

Data: Peak blasts at two pressure levels; impact deceleration. High-resolution T1
MR images.
Tissue level

Adra(Adra, Sun, MacNeil, Holcombe, & Smallwood, 2010) developed a multiscale
3D model of the human epidermis to explore the functions of TGF-β1, a potent growth
factor, during epidermal wound healing. A computational virtual epidermis was created
using an integrated agent/COPASI model, followed by investigation of several
hypotheses, including the changes in epidermal wound healing associated with different
wound sizes.
•

Method: COPASI (COmplex PAthway SImulator)(Hoops et al., 2006) ordinary
differential equations model for sub-cellular TGF-β1 functions, linked to a
cellular agent based model of normal human keratinocytes (NHKs) in FLAME
(www.flame.ac.uk), linked to a multi-cellular layer with a mathematical solver that
resolved physical issues.
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•

Data: Chemical reactions and coefficient factors of TGF-β1 expression and
signaling; biological rules for the behavior of normal human keratinocytes (NHK)
when subjected to injury signals.

Wound healing research has also been used to investigate inflammatory response at
the tissue level. The pathogenesis of vocal fold scarring in humans is not well understood
despite extensive experimental and clinical temporal data from animal studies. Li(N. Y.
Li et al., 2008) developed an agent-based simulation to model the patient-specific vocal
fold inflammation and wound healing following acute phonotrauma.
•

Method: Agent Based Model using NetLogo software

•

Data: IL-1β, IL-6, IL-8, TNF-α, matrix metalloproteinase (MMP)-8, and IL-10
from 4 samples of laryngeal secretions from 9 human subjects.
Cellular/molecular levels

Cellular and molecular level approaches offer novel avenues for investigative
research into disease progression. Computational biology has developed a wide variety of
methods to model cells, molecular interactions in the form of biological pathways, and
molecules at varying levels of abstraction(Mary F. McGuire & Iyengar, 2010 ), along
with extensive databases of results containing inferred and experimentally validated data.
The challenge is to how to modify these methods and use these models and data for
clinical insights into disease progression.
During the past ten years, signaling pathways have become the cornerstone of cancer
research(Dy & Adjei, 2008). Signaling pathways are the primary multilevel, multiscale
communication channels within the organism that regulate physiology(Pawson & Nash,
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2000; Zhang, Ramesh, Uematsu, Akira, & Reeves, 2008); they clearly play important
roles in disease progression. Cellular signaling pathways are initiated by extra-cellular
biological entities including cytokine signaling molecules, hormones and growth factors
in the blood, lymph or interstitial tissue, and biomechanical stimuli such as tissue
strain(Knobloch et al., 2008; Lucitti et al., 2007; Morrow et al., 2007). Because signaling
triggers can be measured noninvasively in biofluids such as serum, urine or saliva, they
may be useful for monitoring the rapid disease progression found in trauma and critical
care. Specific patterns of signaling molecules such as cytokines have been associated
with mortality in septic shock(Waage et al., 1989), critical illness(Roche & Gussler,
1992), trauma(Roumen et al., 1993), and multiple organ failure(Jastrow et al., 2009). In
trauma, the signaling molecules activate a pro-inflammatory systemic
response(Oberholzer, Oberholzer, & Moldawer, 2000) across many pathways to help the
body fight immediate injury; however, if the “turn off” set of signals is not received in
time by the pathways in the cells – or a compensatory systemic response is too much or
too little – death may ensue(Adib-Conquy & Cavaillon, 2009; E. E. Moore et al., 2005).
Molecular signaling profiles may be one of the keys to personalized medicine;
however, there is still much work to be done to make them clinically relevant.
Sachs(Sachs, Itani et al., 2009) created an algorithm to extend acyclic Bayesian network
theory to permit loops, or cycles, in networks. The resulting Generalized Bayesian
Network (GBN) is a Bayesian network model of nodes representing molecular data,
augmented by state nodes and edges representing the statistical dependencies among the
nodes. As a proof of principle, Sachs used GBN to characterize disease states and patient42

specific signaling profiles in human follicular lymphoma tumors following B-cell antigen
receptor stimulation(Sachs, Gentles et al., 2009). The results showed differences in
comparably diagnosed patients that might influence individual prognosis and therapy.
•

Method: Generalized Bayesian Networks (GBN): Bayesian Networks model of
the phospho-protein signaling pathway augmented with state nodes for patient and
disease

•

Data: Flow cytometry measures of six phospho-protein levels (SYK, ERK, p38,
CBL, SFK, BTK) before and after B-cell antigen receptor signaling. Patient state
and disease state.

Another research question is how signaling events trigger cellular responses.
Signaling pathways that lead to apoptosis are of particular interest in disease progression.
Using a data-driven computational technique called Model-Breakpoint Analysis,
Janes(Janes, Reinhardt, & Yaffe, 2008) found that the dynamic range of the molecular
signals had a greater influence on predicting cytokine-induced apoptotic cellular response
than either basal or maximally inducible signal strength; results were validated
experimentally. The results suggest that changes in dynamic range, due to subtle
molecular amino-acid changes from disease mutations, could lead to pathophysiology.
•

Method: Partial least-squares regression, principal component analysis, equationbased model breakpoint analysis.

•

Data: Model of cytokine-induced apoptosis based on 7,980 measurements of
molecular signals that are activated by combinations of the death stimulus, tumor
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necrosis factor (TNF), together with a survival stimuli of epidermal growth factor
(EGF) or insulin.
Petri nets can represent signal transduction networks at varying abstraction levels
using graphs with molecules for nodes, edges for transitions, and tokens generated by the
transitions. Petri net models can be constructed from limited knowledge of the pathway
behavior, with ambiguities resolved through subsequent model validation. Qualitative
Petri net models can be extended to quantitative stochastic or continuous Petri net models
by the addition of rate equations(Heiner et al., 2010 ). Simulations of stochastic models
can be run dynamically, and ordinary differential equation solvers can run static
deterministic analyses of continuous Petri net models. Heiner(Heiner, Koch, & Will,
2004) developed and validated a qualitative Petri net model of apoptotic pathways, using
formal computer science methods to represent pathway structure and behavior. Although
not directly linked to clinical data, Heiner’s Petri net process model could be perturbed to
gain insights into apoptosis not easily seen in other representations.
•

Method: Step-wise incremental Petri net modeling with repeated analyses. Linear
algebra using the incidence matrix and transition vector from the network graph.

•

Data: A published schematic overview of apoptosis, comprising both extrinsic
and intrinsic pathways, induced by DNA damaging and Fas signals, resulting in
DNA fragmentation combined with a Fas-induced MAPK (mitogen-activated
protein kinase) pathway and TNFR-1 receptor-induced pathways. Apoptosis
inhibitors were not taken into account.
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Summary
Research in trauma and critical illness is especially challenging because the effects
of the original insult can be widespread across the entire body, affecting multiple organ
systems. Disease progression is typically rapid, measured in hours and sometimes in
minutes. At present there are growing capabilities to collect vast amounts of temporally
indexed quantitative and qualitative data at multiple levels, from concentrations of
biomolecules to sophisticated imaging modalities. These capabilities have the potential to
support translational “bedside to bench and back” research leading to personalized
therapies. However, the current resources to integrate and interpret patient-specific data
within the context of acute illness are still limited and new computational approaches are
needed(Zenker, Rubin, & Clermont, 2007).
In this chapter I have presented a selection of computational approaches and data
sources primarily from systems biology that can be useful for translational clinical
research in disease progression. Clearly, due to the vast scope and complexity of human
pathophysiology, no one methodology can be a magic bullet. I believe that judicious
selection, adaptation, and application of techniques such as these can yield valuable
insights into the underlying mechanisms of disease progression and help formulate
effective and personalized therapies. In the next two chapters I present the Pathway
Semantics Algorithm, a novel computational method that uses matrix algebra to bridge
biology and medicine for the translational analysis of disease progression.

45

Chapter 3 Pathway Semantics Algorithm: Node Analysis
Rapid advances in lab technologies have made it easier and cheaper to measure vast
quantities of molecular data in biofluids and tissue, resulting in exponential growth in the
amount of quantitative and qualitative data available about molecular pathway
interactions. In 2001, only 18 pathway websites were active(Wixon, 2001). By 2010,
more than 205 million molecular interactions were accessible via the Internet(PathGuide,
2010). There are commercial and publicly available databases of molecular
interactions(Ingenuity, 2010; Tarcea et al., 2009), biological pathways(Caspi et al., 2008;
Elliott et al., 2008; Visvanathan et al., 2008; Wixon, 2001), and genomic correlates(L. T.
Sam et al., 2009).
Increasingly detailed molecular data from patients can be measured in a timely
manner. For example, Luminex’s xMAP technology can measure multiplex analysis of
up to 500 unique analytes in a single test well, generating up to 48,000 data points in less
than one hour(Luminex, 2010). Recently, the technical ability to efficiently measure vast
quantities of patients’ molecular data has moved from the bioscience laboratory to the
patient’s bedside with the advent of lab-on-a-chip sensor technologies(Jokerst &
McDevitt, 2010; Mark, Haeberle, Roth, von Stetten, & Zengerle, 2010) that can support
personalized medicine.
This deluge of molecular data creates opportunities for translational biomedical
research that connects patients’ disease states and molecular data with existing pathway
databases. However there is a dearth of algorithms and computationally tractable methods
that facilitate analysis of bedside-to-bench-and-back information. Researchers have
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called for improved discovery processes(Rifai et al., 2006) and methods for process
quality assessment(Tuglus & van der Laan, 2008). Plausible and meaningful hypotheses
must be derived from a deluge of quantitative and qualitative experimental data that are
spread over a variety of experimental paradigms such as clinical outcome, time, cell cycle
phase, or molecular localization. In addition to analytical methods, there is a need for
ways to uncover new findings that lead to interesting hypotheses.
Studies of scientific discovery have demonstrated that most new findings arise from
data-driven hypotheses generated from unexpected observations rather than from
verification of pre-determined hypotheses based on theories(Klahr & Simon, 1999). In a
bedside-to-bench approach, discovery is driven by patient data collected at the bedside.
Mechanisms or therapies are confirmed later at the lab bench. Data-driven, evidencebased molecular patterns are a fundamental component of personalized medicine
research; the molecular patterns can be used to identify drug targets or candidate
biomarkers.
Notable diagnostic successes based on the molecular patterns found in patient data
include the validation of 14-3-3 proteins found in cerebrospinal fluid (CSF) as diagnostic
of transmissible spongiform encephalopathies(Hsich, Kenney, Gibbs, Lee, & Harrington,
1996) and the validation of a panel of 18 urinary molecules that discriminate antibodyassociated vasculitis from other renal diseases(Haubitz et al., 2009). Overall, my goal is
to advance diagnostic, prognostic and therapeutic knowledge and increase understanding
of the biological mechanisms underlying disease progression.
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The challenge of pathway analysis for shock / trauma
In shock / trauma, cytokine signaling molecules activate a pro-inflammatory
systemic response(Oberholzer et al., 2000) across many biological pathways to fight
immediate injury; however, if the compensatory systemic response is too much or too
little, death or morbidity may ensue(Adib-Conquy & Cavaillon, 2009; E. E. Moore et al.,
2005). Specific cytokines have been associated with mortality in septic shock(Waage et
al., 1989), critical illness(Roche & Gussler, 1992), and trauma(Roumen et al., 1993).
Cytokine activity patterns change rapidly within the first 24 hours of trauma, and sets of
cytokines significantly associated with one outcome at a specific time from insult may
not be associated with any outcome at another time(Jastrow et al., 2009).
Today, immunoassay methods provide highly accurate measurements of cytokine
levels. This measurable cytokine data has great potential for developing therapies that
minimize the occurrence of possibly preventable syndromes associated with trauma such
as multiple organ failure. However, it is difficult to draw inferences about the meaning of
likely molecular patterns without efficient algorithms and techniques. Algorithms that
select and prioritize molecular patterns for further investigation are beneficial because
they can limit the exploration space for in vitro and in vivo hypothesis testing, minimize
risks and costs of experimentation and provide evidence-based information for clinical
trials research.
Current approaches to molecular pattern identification in disease include the use of
high throughput measurement techniques such as mass spectrometry and microarray
immunoassays and qualitative methods such as text mining and graphical analysis. Mass
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spectrometry is the most common technique for “unbiased” discovery where all protein
and peptide components of tissues and biofluids are identified within the capability of the
equipment. Microarray immunoassays are more sensitive and specific; they measure the
concentrations of pre-determined analytes using immunological reactions. Both assay
methods have benefits and drawbacks for clinical usage(Hoofnagle & Wener, 2009). Text
mining algorithms search published literature for information about molecular function
and disease associations while graphical analysis uses algorithms from computer science
to identify subgraph motifs in canonical pathway networks of molecular interactions
found in diseases. Network-based graphical analysis using gene expression patterns has
been shown to generate novel hypotheses about the classification of breast cancer
metastasis, including the finding that some gene associations can only be detected using
network rather than conventional analysis(Chuang, Lee, Liu, Lee, & Ideker, 2007).
Systems biology tools model in silico biological pathway systems using computational
methods that parallel in vitro cell-line and in vivo animal models for hypothesis discovery
and instantiation(Mary F. McGuire & Iyengar, 2010).
There are drawbacks to the current approaches. The most significant molecular
interactions associated with the disease may appear in a non-canonical pathway(W. X. Li,
2008) that text mining and in silico modeling may overlook. Although ordinary
differential equations (ODEs) can provide time-based analysis of biological pathways,
they usually model a small group of canonical pathways within a single cell and are not
easily computable at the organism level. For example, an ODE model of one NFκB
signaling pathway in one cell activated by one TNF-α signaling molecule uses 18
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nonlinear differential equations, with 33 independent variables and 16 dependent
variables in a simplified reaction kinetics model(Cho et al., 2003). Hence, additional
analytical techniques are needed to overcome the research bias towards canonical
pathway associations.
In summary, to develop deeper insights into the mechanisms of disease progression
and to improve treatment, it is useful to examine in detail the biological pathways that are
activated over time, resulting in differential outcomes. Because patterns of cytokines
have been shown to change rapidly in trauma, it is likely that their associated biological
pathways offer clues to the underlying pathophysiology, and perhaps even, what is about
to happen next. The challenge of pathway analysis for shock / trauma is to develop
computationally tractable bedside-to-bench methods that can infer the most likely
biological pathways activated by cytokine signaling, provide an analytical framework to
examine those pathways in terms of biomedical questions, support inquiries about the
relationships among the clinical states and the underlying biological progressions, and
suggest hypotheses as to how treatment might influence physiology to mitigate pathways
that go out-of-control.
Using algebra to understand biological pathways in disease progression
In disease progression, a specific molecular pattern can be associated with a certain
outcome only within a certain time period(Jastrow et al., 2009). The use of a
mathematical representation that enables scalable computation can uncover hidden
molecular patterns associated with disease progression. In particular, representing data in
matrix form can be a way to perform powerful and tractable computations that analyze
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and compare changes in molecular patterns over patient outcome, time and other
stratifications.
Matrices are extensible and computable in n-dimensions; they provide a theoretically
sound structure that can be used for biomedical analysis. Matrices can frame biomedical
questions in a way that can uncover relationships between phenomena and hypotheses
through algebra. In addition, matrices facilitate analysis over multiple stratifications such
as time, outcome, and disease states even with constraints such as a small sample size.
Although the process of converting bio-assay data into matrix representation and using
matrix algebra to answer questions of biomedical interest is non-trivial, once the
framework is set up, a multitude of analyses can be performed.
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Hypotheses

Nature

PSA
Hypotheses

Figure 3-1: Goal of Pathway Semantics Algorithm
The overarching goal of the Pathway Semantics Algorithm (PSA) is to efficiently
generate clinically useful hypotheses about disease progression using matrix algebra
to integrate quantitative and qualitative data.

In this chapter, I present the Pathway Semantics Algorithm (PSA) that first converts
the bioassay data to matrix representations and then performs matrix algebra to generate
clinically useful hypotheses that answer biomedical questions. See Figure 3-1. When
applied to a trauma research study on time-based cytokine patterns related to multiple
organ failure (MOF)(Jastrow et al., 2009), PSA revealed novel patterns – beyond those of
the cytokines – in the evoked biological pathways that differentiated the outcomes of
MOF or non-MOF. The algorithm differs from use of standalone pathway analyses, such
as those performed in Ingenuity Pathway Analysis (Ingenuity® Systems,
www.ingenuity.com), because PSA preprocesses the data before input to Ingenuity
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Pathway Analysis (IPA), tailoring data to the biological and clinical questions under
study.
Herein, the next section outlines the algorithm, followed by a demonstration of PSA
based on serum cytokine protein data from Jastrow’s prospective observational study at a
Level I trauma center(Jastrow et al., 2009). The next section presents the results followed
by a discussion of the matrix algebra approach along with considerations for its
application. The chapter ends with a summary.
Algorithm
PSA first processes the input data to generate biological pathways (Steps 1-2) and
then maps the results to matrices constructed to answer the biomedical questions under
study (Steps 3-4). If biological pathways are already available, for example, from
morphoproteomic tissue analysis(R. E. Brown, 2005), only Steps 3 and 4 need be
performed.
Dimensionality Reduction. This process selects characteristic subsets of the
measured molecules. The assayed molecules are assembled into Significance Sets of
those molecules that statistically differentiate the disease states over the stratifications
under study, such as outcome, time period of measurement, cell cycle phase observed, or
a combination of stratifications. The statistical analysis is utilized as a simple factor
analysis, or feature extraction tool, to identify significant molecules.
Pathway Generation. The Significance Set for each stratification group plus the
statistically observed average values (means or medians as appropriate) for each
molecule in the group are input to a pathway generation algorithm that expands each set
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to include its likely neighboring molecules, based on published literature and pathway
databases. A network diagram is then created of the biological pathways showing the
interactions among the molecules for each stratification group.
Convert Network Diagrams to Matrices. Matrix representations, suitable for the
biomedical questions under study, are created from the network diagrams. The molecules,
or nodes, in the network diagram are mapped to a node matrix (or vector) of molecules
over the disease states; the molecular interactions, or edges, in each network diagram are
converted to a matrix (or vector) of molecular interactions. In the simplest form, the node
matrix has 1 in a row/column cell if the row molecule (or molecular interaction) is
present in the column disease state; 0 otherwise.
Matrix Analysis. Algebra is used to compare the matrices to identify differential
patterns of molecules and molecular interactions of biomedical significance over
outcome, time and other stratifications.
Figure 3-2 illustrates a PSA flow diagram for node analysis as applied to the trauma
study.
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Figure 3-2: PSA flow diagram for shock / trauma study node analysis
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Application
Trauma is the leading cause of mortality in the US among individuals below 45 years
of age. In 2006, 156,000 deaths occurred due to trauma; trauma is the cause of 74% of all
deaths for people ages 15-24(Heron et al., 2008). Multiple organ failure (MOF) – also
known as Multiple Organ Dysfunction Syndrome – is one of the most potentially
preventable syndromes arising from trauma, yet its pathophysiology is not well
understood(Deitch, 1992; Maier et al., 2007). The syndrome is unique in that the organs
that fail are not necessarily injured from the trauma and that late MOF may arise days to
weeks after the initial incident. MOF continues to be a leading cause of morbidity in
patients who survive the initial trauma(Stewart, 2007; Watson et al., 2009).
As previously reported, non-parametric statistical analysis showed that certain
cytokine patterns within the first 24 hours from trauma were associated with the outcome
of multiple organ failure before other symptoms were visible(Jastrow et al., 2009).
Cytokines are small proteins released by stimulated macrophages, monocytes, T cells,
and other cells; they bind to specific receptors to induce a wide variety of local and
systemic responses particularly within the innate and adaptive immune systems(Janeway,
Travers, Walport, & Shlomchik, 2004).
PSA used de-identified patient data from the Jastrow study, extracted from the
UTHSC-H Trauma Research Database with the approval of the Committee for the
Protection of Human Subjects (Institutional Review Board / IRB) of the UTHSC-H
(HSC-SHIS-09-0237). The data included serum cytokine measurements, collection times,
and MOF outcomes for 48 patients from an IRB approved prospective observational
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trauma study conducted in the Shock / trauma Intensive Care Unit (STICU) at Memorial
Hermann Hospital, a Level I trauma center in Houston, Texas from January through
December 2005.
Laboratory materials and methods
Twenty-seven cytokines were measured by Bio-Plex immunoassay. See Table 3-1.
For detailed study methods please see Jastrow(Jastrow et al., 2009).
Table 3-1: Cytokines in the Bio-Plex Human Cytokine 27-Plex Panel
Gene Name

UNIPROT ID

Eotaxin

CCL11

P51671

FGF Basic

FGF2

P09038

G-CSF

CSF3

P09919

GM-CSF

CSF2

P04141

IFN-γ

IFNG

P01579

IL-1β

IL1B

P01584

IL-1ra

IL1RN

P18510

IL-2

IL2

P60568

IL-4

IL4

P05112

IL-5

IL5

P05113

IL-6

IL6

P05231

IL-7

IL7

P13232

IL-8

IL8

P10145

IL-9

IL9

P15248

IL-10

IL10

P22301

IL12 (p70)

IL12A/B

P29459/P29460

IL-13

IL13

P35225

IL-15

IL15

P40933
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IL-17

IL17A

Q16552

IP-10

CXCL10

P02778

MCP-1

CCL2

P13500

MIP-1α

CCL3

P10147

MIP-1β

CCL4

P13236

PDGF-BB

PDGFB

P01127

RANTES

CCL5

P13501

TNF-α

TNF

P01375

VEGF

VEGFA

P15692

Cytokine measurement was performed according to the manufacturer’s instructions
using a Bio-Plex multiplexed suspension immunoassay (171-A11127 Bio-Plex Human
Cytokine 27-Plex Panel, 1 x 96-well, Bio-Rad Laboratories, Hercules, CA). The
characteristics of the assay varied for each cytokine. According to the manufacturer, the
assay working ranges had lower limits of 1.4 pg/ml for MIP-1α to 92.6 for IFN-γ, and
upper limits ranging from 836 pg/ml for MIP-1α to 95,484 pg/mL for TNF-a. Assay
sensitivity (Limits of Detection, LOD) ranged from 0.6 pg/ml for IL-1β to 6.4 pg/ml for
IFN-γ. Intra-assay coefficient of variation (%CV) ranged from 5% for IL-10 and IL-15 to
15% for IFN-γ. Inter-assay %CV ranged from 4% for IL-8 to 11% for IL-6 and
Eotaxin(Zhou, Ma, Fedynyshyn, Tan, & Wang, 2009). There is no record that the
manufacturer’s specifications and %CV’s were confirmed during the lab assays.
Data preparation. To normalize the data to time from injury, measurement times
were adjusted to the estimated time from trauma insult, including transport time by land
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or air, as well as hospital time before the start of the resuscitation protocol. If transport
time was not given, the average time for that mode of transportation (by land or
helicopter) was used. This was done in order to preserve biological relationships over
time so that the cytokine pattern activities “lined up” for analysis.
Of the planned 12,960 measurements, 1,107 were missing; 2,057 were “low” and 74
“high”, due to readings outside the immunoassay range. Rather than discard the low and
high measurements, or reduce the actual measurements to ordinal values, the low and
high readings were converted to numerical values based on the range of each cytokine
value. High was replaced by 150% of the maximum value of that cytokine; low by 50%
of the minimum value of that cytokine. This approach was taken because the nonparametric statistical analysis was itself ordinal - based on rank - to differentiate
outcomes. For example, [5, 2, 7, low, 9] was replaced by [5, 2, 7, 1, 9]. All five data
points were retained and the rank order would be the same. Missing data were treated as
such.
Because the measured molecules were signaling molecules, the number of molecules
available to trigger biological pathways was considered more important than their total
mass. Therefore the cytokine data were converted from pg/ml units to SI units before
input to the software that generated the most likely biological pathways based on relative
concentrations of molecules.
The data were grouped over stratifications to facilitate discrete analysis. This
preserved the original data without making the continuity assumption that the
concentrations of the cytokine molecules varied smoothly between measurement times.
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The cytokine data were partitioned for analysis purposes into 6 groups by time periods:
hours 2–6, 6–10, 10–14, 14–18, 18–22 and 22–24. The four-hour time period was chosen
because that was the scheduled time between clinical measurements.
For clarity and simplicity, the mathematical representation used was limited to
vectors over time in the form of two-dimensional matrices.
Step 1: Dimensionality Reduction
Significance Sets Si=1,I of molecules ci=1,I;a=1,A that statistically differentiated the K
outcomes qk=1,K over time periods xi=1,I were created based on the non-parametric Mann–
Whitney–Wilcoxon (MWW) test executed in each of 6 time periods within the first 24
hours from insult. Outcomes were q1 = MOF (multiple organ failure) or q2 = NMOF
(non-multiple organ failure). Time periods from insult were xi=1,6 = 2–6, 6–10, 10–14, 14–
18, 18–22 and 22–24. The Significance Sets S1, S2 and S6 contained the names of 10 of
the 27 measured cytokines; S3 and S5 contained 14 cytokines; and S6 had 15 cytokines.
The names of the cytokines differed in each Si. For example, S1 contained: c1,1= Eotaxin;
c1,2= G-CSF; c1,3= GM-CSF; c1,4= IFN-γ; c1,5= IL-1ra; c1,6= IL-6; c1,7= IL-8; c1,8= IP-10;
c1,9= MCP-1 and c1,10= MIP-1β. See Table 3-2. Dimensionality reduction was achieved by
selecting for further analysis only the group of cytokine molecules identified as
statistically significant outcome differentiators in each time period – a basic factor
analysis.
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Table 3-2: Significance Sets of cytokines over time
S1

S2

S3

S4

S5

S6

Eotaxin

X

X

X

X

X

X

G-CSF

X

X

X

X

X

X

GM-CSF

X

X

X

X

X

X

IFN-γ

X

X

X

X

X

IL-1ra

X

X

X

X

X

X

X
X

X

X

IL-5
IL-6

X

X

X

IL-7
IL-8

X

X

X

X

X

X

X

X

IL-9

X

X

IL-10

X

IL-13

X

X

X

X

X

IP-10

X

X

X

X

X

X

MCP-1

X

X

X

X

X

X

MIP-1β

X

X

X

X

X

RANTES

X

TNF-α

X

X

X

Si contains the names of the molecules in the Significance Set in time period xi. X
represents the median values vi,a,k for each outcome. Note that the significant
molecules in Si differ by time period, reflecting the dynamic nature of the cytokine
signaling patterns in shock / trauma progression.
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For consistency with the original non-parametric statistical analysis, the statistical
weight vi,a,k was set equal to the median concentrations in pg/ml of each assayed molecule
ci,a in Si for each outcome qk. Table 2 was expanded to 2 tables, one for MOF and one for
non-MOF, with the median values for each outcome in place of the “X’s”.
Step 2: Pathway Generation
Ingenuity Pathways Analysis (IPA) was used to find the likely neighboring
molecules because the software provides a literature and pathway database search along
with a pathway generation algorithm that utilizes weighted lists of molecules (Ingenuity®
Systems, www.ingenuity.com). The algorithm breaks “ties” about which neighbors to add
to an evoked network based on the relative weightings of the input molecules(S.
Ingenuity, 2005). Because the analytes were signaling molecules, the relative numbers of
molecular signals, rather than the relative weights of the molecules, generate more
representative biological pathways(M. F. McGuire, Iyengar, & Mercer, 2007). Therefore,
two additional data modifications were performed. First, the units for the median values
vi,a,k were converted from concentrations in pg/ml to v´i,a,k, the number of molecules per
liter (pmol/L) based on the mass of the cytokine in kDa as reported in UniProt
(www.uniprot.org). Second, certain cytokines must be present in multiples or have
multiple receptors to send signals. Therefore the v´i,a,k were further adjusted to v´´i,a,k by
how many molecules were required for one signal. The adjusted calculation details are
given in the Appendix.
An IPA data template was prepared for each Si with the assayed molecule weightings
v´´i,a,k (intensities) for both outcomes qk in time period xi and the molecule’s
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“Gene/Protein ID”. The molecule was identified by its UniProt Knowledgebase
(UniProtKB) Accession Number, based on the best match for human (subunit A or chain
A). Each v´´i,a,k was entered as an “Observation/Expression k”, with k=1 for MOF and
k=2 for non-MOF. The 6 datasets generated 12 time-stamped network groups with one to
three 35-molecule networks in each group (the default 35-molecule limit is adjustable.)
Each group was exported as a text list of molecules (network nodes) and as a graphic
image of molecular interactions (network edges) The molecules lists were combined to
identify 193 unique subject molecules. See Figure 3-3.
Arginase

IL-2R

'.&$"T$
.;S

Iga

Igm

Il12  receptor

Cpla2
MHC  Class  II

,7E

(";<+==

JAK

;

IL7
Interferon  alpha
IgG

C1q

<-'

&92/

IL5

.!/<S

,62
##!//

Pka
STAT5a/b
V7G@

IKK  (complex)
Nos

1@9A+B@96C45D

Cyclooxygenase

Ap1
Ige

Nfat  (family)

,-($'/N$

IL12  (complex)

IL13
IL10

IFNG

&9:
.G7

##!$

1@E=R&74-

,92E

ERK1/2
Rap1

LDL

IL1RN

KG@+L7A9

#X#!/0

#T<$

#/O
-2/

.!*
##!U

#T<)

(.)'

#249$

.!H
.<1;
.@M+G9669

(E9

HLA-DR

IL8

.!/&1

.<1+=7A9

.G9
.!/0

>!-R"&

CSF3

.''+BI36247JD

>C:A3M7+Q)

RNA  polymerase  II
Tgf  beta

.!/

.!F

K48

Tlr

NFkB  (complex)

SAA@
Histone  h3

.!/$+BI36247JD

TK-KF9NL

Vegf

.G6

.MA78@783M+942Q9

.!?

Mmp
PDGF  BB

-8GCM9:7

13:

>C:A3M7+QU
&1-+23456789:7+..

NfkB-RelA

KSR2

.!/)

%&'/N$

.G;

CCL4
PI3K
ERK

T--W

1<E=+BI36247JD

VCA96CM")RV"&R&X&

Histone  h4

Jnk

Fibrinogen

-EA

()*+,-('

!"!

Hsp70
Ifn  gamma
IL6

Ras

FAK

PME

IFN  Beta

CSF2

CCL2

Mapk
Mek

VitaminD3-VDR-RXR

CXCL10

Akt

P38  MAPK
CCL11

<CL8CM3G7M

%&'

IL1

MAP2K1/2

>:2?0

G

,>#+#49::+..

#5I433J5G7M9:7
.!R$&

P-'

TFF2
-.</

Egfr-Erbb2
DUOX1
.4/$+87I72A38

Figure 3-3: Biological networks differ by disease state
Although the same Significance Set of cytokines was used for generation of both
pathways in a time period, the cytokine median values for each outcome were
different, resulting in different networks: MOF on the left, non-MOF on the right, at
hours 10–14 from trauma. (See Appendix for network details not visible at this scale.)
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Visual inspection shows differences in the biological networks evoked by different
disease states. Shown in Figure 3-3 are the networks for multiple organ failure (left) and
non-multiple organ failure (right) based on patient cytokine data at hours 10–14 from
trauma. Both networks were evoked from the same set of molecules, S3, with different
median concentrations v´´3,a,k for each outcome qk=1, 2. See the Appendix for all 12 graphs
that generated the 193 unique subject molecules.
Step 3: Convert Network Diagrams to Matrices
A summary list Tr of 193 unique subject molecule names mr was assembled from the 12
groups and entered into column 1 of two temporal dependency matrices TDMMOF(mr, xi)
and TDMNMOF(mr, xi), with the headers for columns 2–7 set as the time periods xi and 1 or
0 in row/column cells z denoting the presence or absence of the molecule as depicted in
the example matrices in
Figure 3-4. TDM1 (above), TDM2 (below), show 6 molecules mr over 3 time periods
xi in 2 outcomes qk. To identify molecular patterns by outcome and over time, a summary
list mr was compiled of the names of the molecules present in any of the biological
networks evoked from the assayed molecules. Then a temporal dependency matrix
(TDM) matrix was constructed for each outcome qk, with the molecule names mr as the
first column and the time periods xi as the headers across the remaining columns. If the
molecule was present in the time period in the outcome, a 1 was placed in the
row/column cell zkri; otherwise 0. The rationale behind this process was to facilitate
computational comparisons over time and outcome using matrix algebra and logic.
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Matrix algebra was then used to compare the TDMs over disease state stratifications to
elucidate disease progression and explore questions of biological significance.
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0

0

x1

x2

x3

m1

1

0

1

m2

1

1

0

m3

1

0

1

m4

0

1

0

m5

1

0

0

m6

1

1

1

q2

Figure 3-4: Temporal Dependency Matrices (TDMs) example
TDM1 (above), TDM2 (below), show 6 molecules mr over 3 time periods xi in 2
outcomes qk.
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Step 4: Matrix Analysis
The mapping of pathways to matrices enabled a wide variety of computational
analyses using pathway molecules (nodes) and their interactions (edges) to uncover
hidden network patterns. Two examples of using node analysis follow.
Example 1 Node Analysis. Identify molecules mr that appear at least once in both
outcomes in the same time period xi and at least once in either outcome in a different time
period.
Background: Danger-associated molecular patterns (DAMP) in the systemic
inflammatory response syndrome (SIRS) and sepsis induce the production of pro and
anti-inflammatory mediators by pattern-recognition receptors (PRR). A dysfunctional
acute inflammatory response may lead to MOF(Bianchi, 2007; Castellheim, Brekke,
Espevik, Harboe, & Mollnes, 2009).
Biomedical questions: In this study, are there molecules that are “time-shifted” in
different outcomes? Is a molecular interaction continuing past its “normal” innate
response?
Hypothesis: If the identified molecules appear in both outcomes at different times,
then additional research may show how to modulate those molecules to minimize
negative outcomes.
Let ZMOF =

" z11
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Let Z´NMOF =
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Let Z˝ = ZMOF + Z´NMOF

!

The cells z˝ri of the resulting matrix Z˝ have a 2 if the molecule mr was present in both
outcomes in time period xi, a 1 if it was present in one outcome or the other, and 0 if it
was not present in either. A molecule mr was selected if there was at least one 2 and one 1
in its row. Using these criteria, four molecules were identified that appeared at least once
in both outcomes in the same time period and at least once in either outcome in a
different time period: CIITA, HIRA, IG9, and KSR2.
Example 2 Node Analysis. Identify molecules that appeared only in one outcome or
the other in more than one time period.
Background: Cytokine patterns are associated with different trauma
outcomes(Jastrow et al., 2009; Maier et al., 2007).
Biomedical question: Are there molecules in the pathways triggered by the measured
cytokines that are associated only with one outcome in at least 2 of the 6 time periods
under study?
Hypothesis: Molecules that meet these criteria may reveal underlying mechanisms
that have not yet been associated with specific clinical outcomes.
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Let MOF_SELECT(mr) = 1,
if " zri > 1 # " z$ri = 0 ; else 0

(

!

i=1,I

) (

i=1,I

)

(1)

Based on these criteria, four molecules were identified as appearing only in MOF:
Egfr-Erbb2, IFI6, MRAS and NOD1; no molecules appeared solely in NMOF.
Results
The matrix analysis in Step 4 identified eight molecules from the 193 molecules
evoked by the assayed cytokines whose patterns at different times differentiated
outcomes. Literature searches were performed on each molecule to ascertain associations
with multiple organ failure or other shock syndromes. IG9(Calderon et al., 2000) was
deleted because the molecule’s identification was withdrawn (T. M. Calderon, personal
communication). See Table 3-3.
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Table 3-3: Molecular patterns of multiple organ failure
2–6
CIITA

M, N

EGFR

M*

HIRA

N

6–10

10–14

MRAS
NOD1

M, N
M*

18–22

M

M

M, N

M

M*

M*

22–24

M*

IFI6
KSR2

14–18

M

M

M*
M*

M*

Key M: appears in MOF, N: appears in non-MOF, M*: appears only in MOF. The
header row shows the time in hours from trauma.

Of the seven molecules that differentiated outcomes of MOF or non-MOF, only three
have been previously been associated with shock / trauma: CIITA, EGFR and NOD1.
The citations were retrieved from PubMed on February 6, 2010 based on a search for the
molecule name and the MeSH term “shock,” which includes the following syndrome
categories: Multiple Organ Failure, Cardiogenic Shock, Hemorrhagic Shock, Surgical
Shock, Traumatic Shock, and Systemic Inflammatory Response Syndrome (including
Septic Shock). Following are short descriptions of the seven molecules: CIITA, EGFR,
HIRA, IFI6, KSR2, MRAS, and NOD1, and what they suggest for shock / trauma
progression.
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Molecule 1: CIITA
EntrezGene, UNIPROT ID: EG 4261, P33076
PubMed search: ("shock"[MeSH Terms] ) AND CIITA[All Fields]
Known in Shock: Yes(Le Tulzo et al., 2004; Pachot et al., 2005; Pangault et al.,
2006; Wilson et al., 2008)
Known Functions: CIITA is up-regulated by PPARγ in vascular smooth muscle
cells, which enhances IFNγ-mediated transcription and rescues the TGFβ
antagonism(Kong, Fang, Fang, Li, & Xu, 2009). CIITA directly inhibits viral replication
and spreading; CIITA triggers antigen presentation to CD4+ T cells leading to an
adaptive immune response(Tosi, Bozzo, & Accolla, 2009). Enteral glutamine decreases
infectious complications in trauma by protecting the gut. Glutamine administered to the
post-ischemic gut has been correlated with transcriptional activation of PPARγ. There is
also smooth muscle in the gut; therefore CIITA may be up-regulated due to the PPARγ
activated by the administration of enteral glutamine, which has been shown to be safe
during active shock resuscitation(Santora & Kozar, 2009),(McQuiggan et al., 2008).
Molecule 2: EGFR
EntrezGene, UNIPROT ID: EG 1956, P00533
PubMed search: ("shock"[MeSH Terms]) AND "EGF receptor"[All Fields]
Known in Shock: Yes(Miettinen et al., 1995; Sanchez, Viladrich, Ramirez, & Soley,
2007; Viladrich, Sanchez, Soley, & Ramirez, 2008)
Known Functions: Transactivation of EGFR and ErbB2 protects intestinal epithelial
cells from TNF-induced apoptosis(Yamaoka et al., 2008). EGF is a potential therapeutic
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agent for the treatment of sepsis(Clark, Clark, Hotchkiss, Buchman, & Coopersmith,
2008).
Molecule 3: HIRA
EntrezGene, UNIPROT ID: EG 7290, P54198
PubMed search: ("shock"[MeSH Terms]) AND HIRA[All Fields]
Known in Shock: No
Known Functions: HIRA promotes replication-independent nucleosome
assembly(Eitoku, Sato, Senda, & Horikoshi, 2008).
Molecule 4: IFI6
EntrezGene, UNIPROT ID: EG 2537, P09912
PubMed search: ("shock"[MeSH Terms]) AND IFI6[All Fields]
Known in Shock: No
Known Functions: IFI6 is believed to play a critical role in the regulation of
apoptosis, or programmed cell death and is a marker for interferon beta (IFNB)
activity(Serrano-Fernandez et al., 2009).
Molecule 5: KSR2
EntrezGene, UNIPROT ID: EG 283455, Q6VAB6
PubMed search: ("shock"[MeSH Terms]) AND KSR2[All Fields]
Known in Shock: No
Known Functions: KSR2 regulates insulin sensitivity and glucose(Costanzo-Garvey
et al., 2009). Hyperglycemia associated with insulin resistance is common in critically ill
patients(Van Den Berghe et al., 2001). KSR2 inhibits MAP3K8 (Cot, Tpl2) kinase
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activity and signaling(Channavajhala et al., 2003). Inhibition of MAP3K8 in primary
human cell types can decrease the production of TNF alpha and other pro-inflammatory
mediators such as MAP3K3-mediated IL-8 (EG 283455) during inflammatory
events(Hall et al., 2007).
Molecule 6: MRAS
EntrezGene, UNIPROT ID: EG 22808, O14807
PubMed search: ("shock"[MeSH Terms]) AND MRAS[All Fields]
Known in Shock: No
Known Functions: MRAS is involved with adhesion signaling, inducing lymphocyte
function-associated antigen 1 (LFA-1)-mediated cell aggregation(Yoshikawa et al.,
2007).
Molecule 7: NOD1
EntrezGene, UNIPROT ID: EG 10392, Q9Y239
PubMed search: ("shock"[MeSH Terms]) AND NOD1[All Fields]
Known in Shock: Yes(Cartwright et al., 2007; Chin et al., 2002; Kim et al., 2008;
Nembrini et al., 2009).
Known Functions: Activation of NOD1 has been shown to induce septic shock and
multiple organ injury(Cartwright et al., 2007). NOD1 protects the intestine from
inflammation-induced tumorigenesis(Chen, Shaw, Redondo, & Nunez, 2008). NOD1 is
involved in the direct killing of Helicobacter pylori bacteria in the stomach and
duodenum by epithelial cells(Grubman et al., 2009). Commensal bacteria promote
immune homeostasis via the innate immune receptor NOD1(Chen & Nunez, 2009).
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CIITA, NOD1 and EGFR have been previously associated with shock / trauma. They
maintain intestinal epithelial cell homeostasis during immune and inflammatory
responses and appear in MOF pathways in this study. This is consistent with previous
findings that pathophysiology of the gut (epithelium, mucosal immune system, and the
commensal bacteria) contributes to critical illness(Clark & Coopersmith, 2007)and to
multiple organ failure(Hassoun et al., 2001).
Although four molecules - HIRA, IFI6, KSR2, and MRAS - have not yet been
associated with shock / trauma, their biological functions seem to be consistent with
trauma progression. MRAS appears in hours 2–10 solely in MOF; it is implicated in the
regulation of integrin-mediated leukocyte adhesion in inflammatory and immune
responses(Yoshikawa et al., 2007). IFI6 appears in hours 14–22 solely in MOF; it
regulates apoptosis, suggesting that programmed cell death is essential to MOF(SerranoFernandez et al., 2009). HIRA is observed in non-MOF in the first hours, and later in
MOF. It promotes nucleosome assembly(Eitoku et al., 2008). This may indicate either the
activation of gene transcription or silencing, with different timings associated with
different outcomes. Likewise, KSR2 is associated with both outcomes early on, but
appears solely in MOF in hours 22–24. It regulates insulin sensitivity(Salluh & Bozza,
2008) and, through inhibition of MAP3K8, decreases pro-inflammatory
mediators(Channavajhala et al., 2003),(Hall et al., 2007). Hence, the presence of KSR2
may reflect the up-regulation of pathways in an attempt to modulate the inflammatory
response after injury. This may be an underlying mechanism related to the fact that
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insulin resistance and hyperglycemia are common in non-diabetic critically ill
patients(Van Den Berghe et al., 2001).
Discussion
In this application, PSA identified and qualified 7 molecules in patterns across time
of the progression of multiple organ failure; of these, only 3 had been previously
associated with any shock / trauma syndrome. A literature search confirmed that the
molecules’ biological functions were consistent with the current understanding of MOF.
PSA also highlighted the dynamic nature of trauma response, indicating that molecular
patterns are specific to certain time periods from insult. PSA uncovered novel molecular
patterns in shock / trauma using an unbiased data-driven approach that integrated what
was known about the patient and what was known about molecular interactions. The
appearance of these patterns made sense within the disease context, and suggested
hypothetical answers to the biomedical questions about which molecules differentiated
patient outcomes. All 7 of these molecules were in the evoked biological pathways over
time and were not measured directly. Instead, they were inferred from published literature
documenting molecular interactions.
Although these results provide insights into potential hypotheses that may be useful
in trauma, the quality of this algorithm depends on quality data from assays, literature and
biological pathway databases as well as the statistical and network algorithms used.
Following are some key considerations:
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Quality of the patient data and the assay method. In the MOF application, 8.5%
of the data was missing. Only one assay method was used, and, its working ranges and
limits of detection (LOD) varied depending on the cytokine being assayed.
Quantity of the patient data. Only 11 of the 48 patients had outcomes of multiple
organ failure; however, there were several thousand cytokine measurements taken on a
regular time basis. Because the time periods were based on time from trauma, the number
of measurements differed in each time period, with the fewest being in the first time
period 2–6 due to patient travel time and the time of protocol entry. In comparison, this
sample contained more cytokine data than found in the Trauma Related Database
(TRDB) of the multi-center, multi-year Inflammation and the Host Response to Injury
Large Scale Collaborative Program. As of 2008, the TRDB contained only 80 trauma
subjects with cytokine data sampled irregularly (www.gluegrant.org).
Dimensionality reduction through Significance Sets. Dimensionality reduction, or
limiting the number of variables under consideration, was performed to reduce false
positives, noise and redundancy in the input data and to reduce the computational burden
in subsequent steps. The trade-off was loss of pattern information.
Choice of statistical analysis used to identify Significance Sets. In this exploratory
analysis, I identified six time-based Significance Sets using the Mann–Whitney–
Wilcoxon (MWW) test on two independent samples (MOF or NMOF) over 27 observed
molecules in each time period. MWW was selected because more sophisticated
techniques rely on normality, a condition not satisfied in these data sets. In this
exploratory analysis, I chose to identify six Significance Sets rather than one Significance
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Set from a repeated measures test in order to yield more a detailed understanding of
disease progression. With my focus on inclusiveness for hypothesis generation, I
tolerated the 5% false positive rate in the Significance Sets and the assumption of
independence of the observed molecules. However, if enough data are available,
multivariate methods such as MANOVA could be applied to account for correlations
among the observations. Note that the statistical analysis is being used to judge the
significance of a variable (e.g. a cytokine in a time period), not the significance of a value
(e.g. an observation of a patient’s cytokine in a time period.) Given a larger sample size
with a normal distribution, exploratory factor analysis methods could be used to identify
the Significance Sets.
Quality of the biological pathway knowledge base and the algorithm used to
evoke biological pathways based on assay measurements. PSA used the commercial
product Ingenuity Pathway Analysis. IPA is well accepted in the biological sciences
community as seen in several hundred references in PubMed
(www.ncbi.nlm.nih.gov/pubmed). I chose to use IPA because it is capable of using
concentration data to generate pathway networks, and has the flexibility to generate
biological networks of any size incorporating the closest interaction neighbors to the
input data. To minimize the effects of noise in the data, median values were used as input
to IPA. The default size of 35 nodes per network was used in this study, with 1 to 3
networks generated for each outcome in each time period. Each network group was
combined before matrix analysis, resulting in up to 105 nodes connected by direct and
indirect molecular interaction edges per time period per outcome.
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Changing nature of the biological pathway knowledge base. IPA’s knowledge
base is constantly updated based on current findings. It is likely that somewhat different
networks will be generated from the same input data each time IPA is run, with the
newer, more relevant, knowledge base information added to the old. The earlier
information may have been rescinded or simply only visible in a network larger than 35
nodes.
Biological scope of the generated network. If the biological scope is limited to
certain species or disease states, the generated network will reflect only current
knowledge with the result that potential molecular interactions in other species and
disease states may be overlooked. Since the goal of applying PSA to MOF was to
uncover hypotheses about potential molecular patterns underlying trauma, it was
preferable to run the IPA network generation algorithm without constraints, with the
understanding that some of the molecular patterns identified may need to be verified in
human shock / trauma progression.
Utility of the molecular patterns. The identified molecules may be difficult to
assay clinically due to their primary presence in tissue rather than biofluids, low
concentrations, or lack of existing assays. However, the molecular patterns may be useful
for in vitro and in vivo verification of the underlying biological mechanisms that may
elicit more clinically useful information.
Resource requirements to implement PSA. Published data for time-based analysis
of biofluids and tissues in disease progression may not be readily available although
access to biological pathway algorithms and data ranges from free open source to
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commercial products. This presents opportunities for research studies to collect more data
in areas such as trauma and critical care where rapid changes are seen and rapid response
to changing patient condition is required.
Summary
This chapter demonstrates that PSA is useful in generating novel hypotheses about
the significant molecules, or pathway nodes, in the changing biological pathways within
the first 24 hours of shock / trauma. The PSA matrix algebra approach identified
differential molecular patterns in biological networks over time and outcome that would
not be easily found through direct assays, literature or database searches.
The biological questions of interest in this application of PSA were capable of being
answered by simple matrix constructions. Insights into more intricate biological
questions, such as the influence of crosstalk in disease progression, require more complex
matrix algebra. In the next chapter, PSA is applied to molecular interaction, or “edge”,
analysis of the evoked pathways in shock / trauma.
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Chapter 4 Pathway Semantics Algorithm: Edge Analysis
In recent years, advances in technology have made it possible to measure a wide
variety of molecules and molecular interactions in cell lines, bio-fluids and tissues. The
availability of these data has opened new avenues of biomedical research, and challenged
the scientific community to uncover the meaning of molecular data in contexts ranging
from cell signaling pathways to phenotype/genotype associations to personalized
medicine(Weng, Bhalla, & Iyengar, 1999). Molecular interactions offer a rich source of
information that should be examined in detail to further understand their roles in disease
progression and outcomes. Computer scientists, mathematicians, physicists, and
industrial engineers are joining biologists and medical researchers to develop new
quantitative and qualitative analytical methods to answer questions about underlying
biological mechanisms and therapeutic efficacies. Algorithms driven by patient data that
incorporate knowledge bases of molecular patterns are of particular interest because of
their potential for hypothesis generation in personalized diagnosis, prognosis, and
therapies. Such algorithms are the focus of my research.
The Pathway Semantics Algorithm (PSA) described in Chapter 3 generates the most
likely biological pathways evoked from patients’ molecular data over stratifications such
as time and/or outcome, and then converts the pathway graphs to matrices of various
formats depending on the biomedical questions being studied. In the pathway graph and
the transformed matrix, there are two major types of entities: nodes that correspond to
specific bio-molecules and edges that correspond to the interactions among the
molecules. The transformation of graphs to matrices enables the application of powerful
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techniques from matrix algebra to develop mathematical comparison methods, analyses,
and metrics leading to useful insights into disease progression across time and clinical
outcomes.
For example, in the PSA node analysis of Chapter 3, I focused on the molecular
components of pathway graphs and developed a matrix format called a Temporal
Dependency Matrix that was instrumental in revealing novel molecular patterns evoked
from patient data over time in shock / trauma, where disease progression is rapid yet not
clinically visible. The computational results predicted seven molecules, based on input
from the original assays, associated with the biological mechanisms underlying multiple
organ failure; only three had been previously recognized as associated with any shock /
trauma syndrome. In this chapter I turn my attention to the edges of pathway graphs,
corresponding to interactions between molecules including genes, RNAs, proteins, or
chemicals. I applied matrix methods to investigate patterns of molecular interactions
across time and across clinical outcomes in terms of four functional relationship
categories: activation, expression, transcription and inhibition. Applying graph theory and
linear algebra, I found that the interaction patterns of relationship sub-graphs changed
rapidly within the first 24 hours of trauma insult, and that these patterns differed across
clinical outcomes of multiple organ failure (MOF) and non-multiple organ failure (nonMOF). In addition, I developed a numerical metric of crosstalk in molecular pathways
called XTALK. In contrast to current practice that merely classifies a network in strictly
binary fashion as having crosstalk or not, XTALK quantifies crosstalk among molecular
interactions from 0% to 100%, thereby leading to a deeper, fine-grained understanding of
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crosstalk and its variation due to disease progression. These methods were applied to the
same shock / trauma data set used in the previous chapter. Results obtained suggest that a
diagnosis, prognosis or therapy based on molecular interaction mechanisms may be most
effective within a certain time period and for a certain functional relationship.
The following sections present background information and definitions relating to
molecular interactions and mathematical notation, followed by a description of the
application of the Pathway Semantics Algorithm to analysis of molecular interactions in
the first 24 hours of trauma progression, the results and a discussion of their meaning,
concluding with my plans for future work.
Background
At a sub-cellular level, molecular interactions can be analyzed using the rules of
biochemistry when they are represented as sets of differential equations. However, due to
computational complexity and lack of interaction parameter rate data, this approach is not
suitable for larger comparative analyses. Instead, molecular interactions, such as proteinprotein or gene-protein interactions, are commonly combined into biological pathway
networks represented as graphs, where the node, or vertex, is the molecule and the edge is
the interaction. This representation facilitates the use of qualitative and quantitative
methods derived from graph theory and algebra because the same biological pathway
network graph can be mapped to a matrix in different ways, allowing for a choice of
mathematical methods appropriate to the biomedical question under study.
Recently, interest has shifted from analysis of nodes, or vertices, in biological
pathway networks, to examining edges, or links between the nodes(Ahn, Bagrow, &
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Lehmann, 2010; Evans & Lambiotte, 2009). This parallels the current research into “link
communities” in social networks, where one person may be connected to several
overlapping communities of home, work, and interests. In both social and biological
networks, the edges are directional, showing the influence from one node (a person or
molecule) upon another in a multi-directional cascade.
Biological link communities also overlap; a molecule may participate in several
different interaction categories simultaneously with the same target molecule, or
inversely, several interactions may occur simultaneously with different molecules to
achieve the same target function. This latter property has been defined as degeneracy –
the ability of structurally different elements to perform the same function or yield the
same output; in contrast, redundancy requires identical elements to perform the same
function(Edelman & Gally, 2001; Tononi, Sporns, & Edelman, 1999). Degeneracy is a
key property underlying the robustness of complex adaptive biological systems, such as
the immune system(Macia & Sole, 2009; Tieri et al., 2010; Whitacre, 2010).
Crosstalk in biological pathways can be defined as consisting of the redundant
signaling messages sent over degenerate edges that achieve the same biological function.
This is consistent with Bruni’s definition that crosstalk exists when edges are functionally
compatible to, or dependent, on other edges(Bruni, 2007). Crosstalk relates to how
pathways determine functional specificity, how ubiquitous messengers transmit specific
information, and how similar messages crosslink within the system while undesired
signals are minimized. Quantifying crosstalk in patient data-driven biological pathways
can give insights into the relative robustness of different biological functions and suggest
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timing and approaches for therapies directed at pathway modulation. For simplicity, this
study measured crosstalk in one molecular interaction function at a time in each pathway;
cascades of “mixed-function” molecular interactions that overall would result in
execution of the same target function were not considered.
Additional definitions
Notation and definitions used correspond to those used by Ingenuity Pathways
Analysis (IPA)(Ingenuity, 2010). The term node is used rather than vertex.
A molecule is any gene, RNA, protein or chemical. A molecule is represented by a
node on the directed graph of a biological pathway.
A relationship is a functional interaction from one molecule to another. A
relationship is represented by an edge on the directed graph of a biological pathway. A
directed graph, in mathematical terminology, has specific properties that can be exploited
computationally. IPA designates relationships as direct or indirect, in a different sense of
the word “direct”. A direct relationship is a direct physical contact interaction between
the two molecules. It is represented by a solid line edge. An indirect relationship is an
interaction that does not require physical contact but is explicitly documented in the
literature. It is represented by a dotted line edge. A relationship graph is a directed graph
whose edges are in the same relationship category. Molecules or edges are called
invariant when they are the same in different stratifications. For example, edges are
invariant over all time in one outcome if they do not change over all time periods for that
outcome; alternatively, edges are invariant over outcome if they are the same in both
outcomes in one time period or more as specified.
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Let B(E,N) be a directed graph with E edges and N nodes that represents a biological
pathway with relationship interactions as edges and molecules as nodes. Then A is a
relationship sub-graph of B with A ⊆ B when ∀ E in A are in the same relationship
category.
Pathway Semantics Algorithm for Edges
Step 1 and Step 2. The Pathway Semantics Algorithm (PSA) first processes the
input data to generate biological pathways (Steps 1-2) and then maps the results to
matrices constructed to answer the biomedical questions under study (Steps 3-4). For
details of Steps 1 and 2 of Pathway Semantics, please see Chapter 3. For this edge
analysis, relationship sub-graphs were extracted from each pathway for each selected
molecular interaction relationship within each outcome and time period. The sub-graphs
were represented as cyclic digraphs (directed graphs with cycles). Each directed edge, or
arc, of a sub-graph was a one-way interaction relationship from one molecule to another.
The sub-graphs could also contain loops, or cycles because feedback, feed forward, and
self-loops occurred in molecular interactions. This necessitated the use of incidence
matrices for computation and limited graph metrics to those for cyclic digraphs.
Step 3. Map graphs to matrices.
In Step 3, the pathway networks were mapped to matrices. Each relationship subgraph was mapped to an incidence matrix, called an Edge-Molecule (EM) matrix, where
each row represented a from-to edge, and each column represented a molecule, with
doubles for self-loops. A -1 was placed in the from molecule column, a +1 in the to
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column and 0 otherwise. All molecules evoked in the study were placed in the column
header row.
Definition. The incidence matrix M = [mij] of a directed graph B = B(E,N) is a E x N′
matrix, M(E,N′) where E = number of edges and N′ = number of nodes (with duplicate
nodes for self-loops) such that mij = -1 if edge i leaves node j, +1 if edge i enters node j, 0
otherwise(Bondy & Murty, 2008).
Step 4. Compare biological pathways using matrices
In Step 4, algebraic comparisons were performed across stratifications. First, a
descriptive analysis was performed to count the number of edges in each relationship in
each outcome over time and to identify edges that were unchanged over time and
outcome. Linear algebra was then used to calculate XTALK, the crosstalk for each
relationship, time period, and outcome. With the XTALK measure, relationship subgraphs could be analyzed to uncover which functional relationships have the most or the
least crosstalk in different outcomes and how crosstalk changes over stratifications such
as time. The XTALK measure is based on the calculation of matrix rank:
Definition. The rank R of a matrix M is the maximal number of its linearly
independent columns or rows(Birkhoff & MacLane, 1953). Rank can be calculated using
Gaussian elimination or singular value decomposition.
If rank R is greater than or equal to E, the number of edges (rows), then all the edges
act independently. The percentage, or ratio, of independent edges = R/E, and the ratio of
dependent edges is 1 - R/E.
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I propose the biological interpretation that the maximum number of independent
molecular interactions (edges) required for a molecular function is the same as the rank of
the incidence matrix constructed from the functional relationship sub-graph, and that a
measure of crosstalk for that function can be based on the percentage of dependent edges.
Definition. The XTALK ratio of a directed graph B = B(E,N) with incidence matrix
M(E,N′) is defined as 1 - (rank (M(E,N′))/E).
If XTALK = 0%, then all edges act independently for a particular function. The
XTALK measure includes normalization by the total number of edges in a graph to allow
comparisons of crosstalk over time and outcome.
To illustrate the graph mapping to the incidence matrix, see Figure 4-1 and Table
4-1, representing a network with 3 edges and 3 nodes. The calculated rank of the
incidence matrix for the graph is 2. This means that 2 edges are independent and 1 edge is
dependent. It can be seen that the path along the edge_A_C is a combination of
edge_A_B followed by edge_B_C. The network shows the property of degeneracy: the
target function can be achieved by edgeA_C or by the edgeA_B followed by the
edgeB_C. With rank R = 2, and the number of edges = 3, XTALK = 1-(2/3) = 33%,
suggesting there exists one-third crosstalk in the biological functional relationship
represented by the graph.
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Table 4-1: Incidence matrix for Figure 4-1

A

B

C

A

B

C

edge_A_B

-1

1

0

edge_B_C

0

-1

1

edge_A_C

-1

0

1

Figure 4-1: Graph example

On completion of Step 4, the results were reviewed in the light of published
literature and expert opinion to generate targeted hypotheses about the molecular
mechanisms of disease progression that may be verified clinically or in the lab.
Application
As mentioned in Chapter 3, trauma is the cause of 74% of all deaths for people ages
15-24(Heron et al., 2008). Disease progression in shock trauma is rapid and deadly;
patients who survive the initial trauma may suffer morbidity from potentially preventable
syndromes such as multiple organ failure (MOF)(Stewart, 2007; Watson et al., 2009).
The pathophysiology underlying MOF is still unclear(Deitch, 1992; Maier et al., 2007).
Patterns of signaling molecules called cytokines(Janeway et al., 2004) have been
associated with patient outcomes in trauma and critical care for some time(Hranjec et al.,
2010; Jastrow et al., 2009; Roumen et al., 1995; Visser, Pillay, Koenderman, & Leenen,
2008; Vodovotz, 2010) and analysis of the biological pathways evoked from cytokines
may offer insights into disease progression.
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De-identified patient data from the Jastrow study(Jastrow et al., 2009) were extracted
from the UTHSC-H Trauma Research Database with the approval of the Committee for
the Protection of Human Subjects (Institutional Review Board / IRB) of the UTHSC-H
(HSC-SHIS-09-0237). The data included serum cytokine measurements, collection times,
and MOF outcomes for 48 patients from an IRB approved prospective observational
trauma study conducted in the shock / trauma Intensive Care Unit (STICU) at Memorial
Hermann Hospital, a Level I trauma center in Houston, Texas from January through
December 2005. Twenty-seven cytokines were measured by the Bio-Plex Human
Cytokine 27-Plex Panel.
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Table 4-2: Eleven cytokines were used for PSA edge analysis
Gene Name

UNIPROT ID

Eotaxin

CCL11

P51671

G-CSF

CSF3

P09919

GM-CSF

CSF2

P04141

IFN-γ

IFNG

P01579

IL-1β

IL1B

P01584

IL-1ra

IL1RN

P18510

IL-2

IL2

P60568

IL-6

IL6

P05231

IL-8

IL8

P10145

IL-10

IL10

P22301

TNF-α

TNF

P01375

Although all 27 cytokines were used in the previous PSA molecule (node) study,
only 11 were used in this edge analysis due to export limitations of the pathway
generation software (Ingenuity Pathway Analysis) and the fact that all edges had to be
manually transcribed. The 11 cytokines were chosen by the shock trauma clinicians as
those most likely related to multiple organ failure. See Table 4-2. In addition, the analysis
was limited to three time periods: hours 6–10, 10–14, and 22–24 hours from trauma; two
outcomes: multiple organ failure (MOF) and non-multiple organ failure (non-MOF); and
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four relationship categories of molecular interactions: activation, expression (including
metabolism and synthesis for chemicals), inhibition and transcription, for a total of 24
pathway network graphs. The relationships are defined by Ingenuity Systems (Ingenuity
Systems, personal communication) as follows:
•

Activation: includes activation events such as activation, activity, stimulation,
reactivation, and specific activity.

•

Inhibition: includes inhibition events such as inhibition, desensitization,
inactivation, repression and autoinhibition.

•

Expression: includes expression events such as expression, upregulation,
downregulation, translation, production, microRNA targeting, and induction.

•

Transcription: includes transcription events such as including transcription,
germline transcription, transactivation, and transrepression

Both direct and indirect interactions were used in the edge analysis. Direct
interactions required that two molecules make direct physical contact with each other and
included chemical modifications, such as phosphorylations, if there was evidence that the
two factors involved interacted directly rather than through an intermediary. Although
indirect interactions did not require physical contact between the two molecules, the
interactions had to be explicitly stated in the literature – not inferred(Ingenuity, 2010).
The edge analysis was performed for each relationship, time, and outcome using the EM
matrices, generating edge counts and crosstalk as defined in Section 3. The IPA pathway
network graphs for this analysis were generated from September to November 2008.
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Results
Steps 1 and 2 of PSA evoked 24 IPA network graphs of the most likely biological
pathways. Note that multiple graphs for an outcome in a time period were consolidated
into a single graph. A total of 1,264 edges were examined among the 132 molecules
evoked in the first 24 hours from insult; each edge was identified by its outcome, time
period, “FROM” molecule, “TO” molecule, and molecular interaction relationship
category. See Figure 4-2 for one graph; all are shown in the Appendix.
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IL1RAP

IL-1R/TLR
IRAK4

IL1F9

MYH11
Akt
IL1R1

IRAK2

IL-1R
IL1F6

Jnk
Mapk
IL1
PDGF BB

PI3K
TFF2

IL1F8

Ap1

Tgf beta
IKK

IL6
IL8

Ras

CSF2
FCGR1C
P38 MAPK

DEFCR3

Mek1/2

CSF3

IL10
Ige

STAT5a/b
RNA polymerase II
CCL11

MHC Class II

Figure 4-2: Evoked biological pathways in MOF at hours 6–10
The “expression” interaction edges are highlighted in gray. White nodes are the
evoked “nearest neighbor” molecules; shaded nodes are the input molecules in the
Significance Set. The darker the shade, the higher the measured median value.
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EM Matrices
In Step 3, the edges were mapped into twenty-four EM matrices by outcome, time
period, and category. Duplicate molecule columns were added to the 132 molecule
columns in all EM matrices to include the 12 molecules that had self-loop interaction
edges. This was required to enable the from-to edge. The 12 molecules with self-loop
feedback were: CCL11, CCNA1, Cyclin A, Cyclin E, IL6, TNF, IFNG, IL1, IL10,
Hsp70, RARB, and MYBL2. The final number of columns in each EM matrix was 144,
with the number of row edges changing according to the interaction type and the time
period. Figure 4-3 shows a portion of the EM matrix for the Figure 4-2 graph.

IL1

IL8
CSF2
IL6

CSF3

IL10

MOF 6_10
0 expres
ssion
FROM_TO

CSF2

CSF3

IL1

IL6

IL8

IL10

CSF3_IL8

0

-1

0

0

1

0

CSF3_IL6

0

-1

0

1

0

0

CSF3_IL10

0

-1

0

0

0

1

IL1_CSF3

0

1

-1

0

0

0

CSF2_CSF3

-1

1

0

0

0

0

Figure 4-3: Section of EM matrix for network shown in Figure 4-2
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Edge Counts
Dominant functions. Based on the Step 4 edge count, the most interactions per time
period were in the activation function category, except in hours 22–24 for non-MOF
when activation interactions were fewer than expression interactions. Inhibition and
transcription interactions were most active in hours 10–14. See Figure 4-4.

Figure 4-4: Edge interactions over time, outcome, and functional relationship
Results show the most activity in hours 10–14 from trauma.
Invariant interactions across all time. No inhibition interactions were consistently
present during the three time periods. Two transcription interactions were present in both
MOF and non-MOF: PDGF BB, which is involved in the transcription of CSF2 (GM94

CSF) and IL1 (IL-1β), which increases transcription of IL8. PDGF BB is a plateletderived growth factor homodimer that causes mitosis in cells of mesenchymal origin;
here it affects the transcription of CSF2, which encodes a cytokine that controls the
production, differentiation, and function of granulocytes and macrophages. IL1 is a
cytokine produced by activated macrophages that mediates the inflammatory response, in
this case by increasing transcription of IL8, a chemokine that functions as a neutrophil
polymorphonuclear cell (PMN) chemoattractant. It is also a potent angiogenic factor.
Unique interactions in each time period. Although the majority of molecular
interactions were similar in each time period over both outcomes, distinct differences
were revealed by a count of the edges unique to MOF or non-MOF. See Figure 4-5. In
hours 6 to 10 from trauma, there were twice as many unique activation interactions in
non-MOF than MOF; whereas by hours 10–14, MOF surpassed non-MOF with a greater
number of unique interactions in all categories. In hours 22–24, MOF had twice as many
unique activation edges than non-MOF, although both had the same number of unique
expression edges. There were few unique inhibition or transcription interactions. Overall,
there were more interactions that appeared solely in MOF than in non-MOF. Another
point of interest is that IL6 was involved in ~50% of the unique expression interactions in
both outcomes in the first 6–10 hours, while IFNG became dominant in hours 10–14.
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Figure 4-5: Unique edge interaction counts
These edges are in addition to the invariant interactions in each time period that are in
both outcomes.

Crosstalk
XTALK, a measure of crosstalk based on the dependency between the functional
edges as calculated by matrix rank, ranged from 0% to a high of 71%, and changed over
time. See Figure 4-6.
Activation. Activation crosstalk was calculated at ~69% in hours 6–10, staying
steady to 71% at hours 10–14, and decreasing in hours 22–24 to 45% in MOF and 32% in
non-MOF.
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Expression. In hours 6–10, expression edge crosstalk was 51% in MOF and 46% in
non-MOF. This increased in hours 10–14 with MOF rising to 62% and non-MOF to 54%.
Crosstalk then decreased in hours 22–24 to 27% in MOF and 31% in non-MOF.
Inhibition. There was no crosstalk in inhibition interactions in hours 6–10 and 22–
24; however, crosstalk increased to 17% in MOF and 20% in non-MOF in hours 10–14.
Transcription. 9% transcription crosstalk was calculated in both outcomes in hours
6–10, rising to ~21% in hours 10–14, then decreasing to 0% by hours 22–24.

80.00%
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%
MOF 6-10

nMOF 6-10 MOF 10-14 nMOF 10-14 MOF 22-24 nMOF 22-24

activation

expression

inhibition

transcription

Figure 4-6: Crosstalk in functional relationships across time and outcome
Percentages calculated using the XTALK measure.
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Interaction Summary
Activation. In hours 6–10, there were twice as many unique activation edges in nonMOF compared to MOF; however the reverse was the case in the later time periods. This
may imply that in non-MOF, a large number of favorable molecular interactions were
underway early, so fewer unique activations were needed as the pathways approached a
favorable outcome of non-MOF. The percentage of activation crosstalk was about the
same in hours 6–10 and 10–14 in both outcomes, decreasing only in hours 22–24.
Expression. By hours 10–14, MOF had more than three times the number of unique
expression edges than non-MOF, implying higher energy consumption in MOF
metabolism than in non-MOF at this time. The percentage of expression crosstalk was
slightly lower in non-MOF than MOF in the first two time periods, changing to slightly
higher by the end.
Inhibition. Unique inhibition interactions appeared solely in MOF in the last two
time periods. Crosstalk appeared in both outcomes only during hours 10–14; it was
slightly higher in non-MOF. Again, this suggests an attempt to damp down molecular
interactions in both outcomes starting in hours 10–14 that was continued in hours 22–24
by additional unique inhibitory interactions in MOF.
Transcription. Unique transcription interactions appeared in both outcomes in hours
10–14, with the majority in MOF. Crosstalk in transcription interactions increased
initially, and disappeared in both outcomes by hours 22–24 when only two transcription
interactions occurred in each outcome.
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Discussion
Today it is generally accepted that there is a need to develop computational, datadriven algorithms to exploit the vast quantity of molecular information available in
knowledge bases in order to advance systems biology and to improve patient
care(Aristotelis, 2006; Wenyuan Li, Xu, & Zhou, 2010 ; Ruths, Nakhleh, Iyengar, Reddy,
& Ram, 2006; Tipney et al., 2009; Veliz-Cuba, Jarrah, & Laubenbacher, 2010). Due to
several successes(Kanehisa, Goto, Furumichi, Tanabe, & Hirakawa, 2009; Sachs, Gentles
et al., 2009; L. Sam, Liu, Li, Friedman, & Lussier, 2007), in silico hypotheses generators
are no longer denigrated as “fishing expeditions”(Brent & Lok, 2005).
The Pathway Semantics Algorithm (PSA) is an initial in silico data integration and
analysis step towards formulating hypotheses about disease progression for personalized
diagnosis, prognosis, and therapies that can be validated in the laboratory and in the
clinic. PSA is based on a novel, flexible approach that uses graph theory and numerical
algebra to computationally compare non-canonical biological pathways evoked from
patient data over time.
PSA was applied to a prospective observational study of shock / trauma, a research
area where patient data is sparse and difficult to obtain even at a Level I trauma center;
randomized controlled trials are not an option. By using patients’ molecular cytokine data
to evoke non-canonical biological pathways from the Ingenuity Pathway Knowledge
Base, PSA expanded the existing information to include the most likely molecules and
molecular interactions evoked by the patients’ cytokines. With the expanded information
set, and its representation as pathway graphs, PSA was able to use computational tools
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and algorithms from graph theory and numerical algebra to compare patterns of
molecules and molecular interactions over different stratifications. In particular, PSA was
able to analyze patterns over time – an absolute necessity for clinicians who treat disease
as it unfolds(Shahar, 2000). This feature shows the potential of PSA to support temporal
reasoning in medical decision-making and support systems.
Overall response to trauma insult
The results from these analyses suggest that molecular interaction activity – and the
nature of that activity – changed dramatically within the first 24 hours of trauma. In both
outcomes, the number of interactions peaked during hours 10–14 from insult, lessening to
about half of the initial activity by hours 22–24; this may be due to the effects of
interventions during the first 24 hours combined with the innate systemic response. There
were core sets of molecular interactions that were invariant over outcomes in each time
period plus unique interactions only in one outcome or the other. This suggests a primary
molecular response to the injury that was modulated by the unique interactions edges
towards favorable or unfavorable outcomes. MOF had fewer unique interactions early in
response, but by hours 10–14, MOF had almost three times as many unique edges as nonMOF – perhaps an excessive number.
Changes in the gene regulation process
Multiple organ failure has been characterized as an adaptive, multilevel time-based
stress response with marked changes in gene expression(Adib-Conquy & Cavaillon,
2009; Cobb, Buchman, Karl, & Hotchkiss, 2000; Warren et al., 2009). I believe that this
is the first study to quantify the changing aspects of gene expression in MOF over time.
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By examining edge interactions in silico, changes in functional relationships and their
crosstalk over time and outcome were revealed.
Molecules must be activated before they can be transcribed and then expressed, and
inhibition can halt any step in the gene regulation process. It is known that cells respond
quickly to stress by altering their metabolism; they can induce apoptosis or cell-cycle
arrest and alter nuclear pathways for DNA repair(Boulon, Westman, Hutten, Boisvert, &
Lamond, 2010). Activation interactions dominated the initial response in both outcomes
through hours 10–14, showing the immediate cellular response to stress. Expression was
higher in MOF, suggesting a higher metabolic load on the system. Inhibition and
transcription interactions were a small proportion of the overall count.
Crosstalk changes over time and outcome
For demonstration purposes, I performed a simple analysis that did not include
interaction cascades of different functions in order to focus on a “black box” of four
dominant functions. Even with this limitation, differences were observed across time and
outcome. This is important because it suggests that a diagnosis, prognosis or therapy
based on molecular data might only be valid within a certain time period and for a certain
functional relationship, due to the degeneracy in the biological network. For example,
because there appear to be few inhibition relationships and little or no inhibition crosstalk
in initial trauma, it may be worth exploring increasing inhibition interactions early on in
order to limit the excessive unique expression interactions in MOF in hours 10–14.
Crosstalk decreased over time in the first 24 hours from trauma, suggesting that therapies
should consider time from insult as well as which interaction functions they are targeting
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in order to be effective. This also suggests that trauma therapies may have to be
administered in a particular sequence, similar to certain cancer therapies.
Study considerations and limitations
The quality of the PSA results depends on the quality of the patient data, the clinical
study protocol, the assay method, the choice of statistical analysis, and the accuracy of
the biological pathway networks generated by the Ingenuity Pathway Algorithm from its
knowledge base. Some key considerations for this edge analysis are as follows:
Age of pathway data. IPA generated the biological networks evoked in this study in
Fall, 2008. Since that time, there have been extensive, continuous updates to the IPA
knowledge base. It is not possible to access older versions of the knowledge base
(Ingenuity Systems, personal communication) nor is it possible to export interaction data
in other than graphical formats, resulting in extensive manual transcription before
computation can be done. Therefore, this chapter is intended as a demonstration of the
algorithm, and the actual biomedical results may differ somewhat based on current
research. My assumption is that the evoked biological networks will primarily be the
same, with the difference that new discoveries may bring new “closest neighbors” into
the graph, pushing out existing molecules past the default 35 node limit per graph. This
can be addressed by generating new graphs with larger node limits. In addition, the
relationships between molecules may be augmented with new relationships or reclassified
to related relationships. However, as with published research, older information about
relationships is rarely deleted.
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Incomplete pathway data. Some functional relationships may be more highly
represented in the Ingenuity Pathways Knowledge Base than others due to the type of
experiments performed in the published research, rather than the reality of the true
proportion of those relationships in nature. This was addressed in the crosstalk
calculation by normalizing XTALK by the number of edges in each relationship subgraph to facilitate comparison across stratifications.
Linearity assumption. Using matrix rank as a basis for the XTALK measure
implies that the edges are related in a linear manner – that is, each edge can be
represented as a combination of nodes with coefficients of -1, 0, or 1. This can be
considered to be a linear approximation to a non-linear function, computed by taking the
first term in the representative Taylor series.
Conclusions and Future Work
The Pathway Semantics Algorithm identified different patterns of molecular
interactions over time, outcomes, and functional relationships in biological networks that
would not be easily found through direct assays, literature or database searches. The
differences in the number of edges, the number of unique edges, and the XTALK ratios
show the utility of evaluating a molecular interaction not just as a connection between
two molecules, but as a directed interaction from one molecule to another that may carry
out one or many specific functions(Wu, Zhang, Yu, & Ouyang, 2009). The crosstalk
measure XTALK provided a novel perspective on the changing functional interaction
relationships in disease progression; the results supported the existence of the property of
degeneracy in biological networks.
103

Chapter 5 Experimental Results / Findings
Introduction
The Pathway Semantics Algorithm was validated by experimental findings in the
disease domain of hemophilia A in an ongoing study of the cellular immune response to
factor VIII (FVIII), an essential blood-clotting factor. The study is being conducted by
Keri Csencsits Smith, PhD, Assistant Professor, Department of Pathology and Laboratory
Medicine at the University of Texas Medical School at Houston.
Background
Hemophilia A is a disease characterized by a deficiency in FVIII clotting activity
that results in bleeding episodes. The disease is managed by intravenous infusions of
FVIII after the onset of bleeding, and, in severe cases, by prophylactic infusions of FVIII
concentrate several times during a week to prevent spontaneous bleeding(Brower &
Thompson, 1993). However, as many as one-third of hemophilia A patients develop
inhibitor antibodies to FVIII, and these patients can no longer receive infusion
therapy(Zakarija et al., 2011). Alternative therapies to manage hemophilia A patients
with FVIII inhibitors are expensive and not often successful.
Several causes, including genetics and inflammatory response, have been proposed
that may influence the production of inhibitor antibodies. Dr. Csencsits Smith’s project
focuses on cytokine signaling. Because specific cytokines mediate T cell help for B cell
antibody production(Bray et al., 1993), modifying cytokine response may prevent or
reduce inhibitor formation. Recently, T cells that secrete IL-17 (known as TH17 cells)
have been linked with the development of inflammatory disease(Korn, Bettelli, Oukka, &
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Kuchroo, 2009). A compound called colonization factor antigen I (CFA/I), derived from
human enterotoxigenic Escherichia coli, has been shown to decrease TH17 response and
increase the number of T cells that can regulate the immune response(Jun et al., 2005;
Kochetkova, Trunkle, Callis, & Pascual, 2008; Ochoa-Reparaz et al., 2008).
The Pathway Semantics Algorithm (PSA) was used to assess how CFA/I treatment
modified the immune response in a mouse model by examination of the pathway
networks evoked from cytokine profiles over time. The hypothesis was that CFA/I would
reduce the formation of inhibitor antibodies by decreasing TH17 response. PSA was then
validated in the laboratory by confirmation of the presence of a predicted molecule from
mouse splenocyte culture supernatant.
Materials and Methods
Laboratory. FVIII-deficient mice (B6;129S4-F8tm1Kaz/J; Jackson Laboratories)(Bi
et al., 1995) were intravenously immunized with 2 µg recombinant human FVIII
(Kogenate®; Bayer) weekly for 4 weeks. This protocol resulted in the production of
anti-FVIII antibodies with inhibitory capacity(Qian, Borovok, Bi, Kazazian, & Hoyer,
1999; Reipert, Ahmad, Turecek, & Schwarz, 2000). Production of inhibitor antibodies
was confirmed by Bethesda assay. Beginning 3 days before the initial FVIII
immunization, mice received either 100 µg of colonization factor antigen I (CFA/I)
isolated from human enterotoxigenic Escherichia coli (E. coli) fimbriae or control sterile
phosphate-buffered saline (PBS) via intranasal instillation. Mice were euthanized on days
7, 14 and 28 post-primary FVIII injection, and splenocytes were isolated and cultured for
72 hours in PRMI-1640 media + 10% fetal bovine serim (FBS). Tissue culture
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supernatants were harvested and used as directed in a MILLIPLEX™ Mouse
Cytokine/Chemokine 22-plex Panel
(www.millipore.com/catalogue/item/mpxmcyto70kpmx22) and results analyzed by
Luminex 100. 22 cytokines were measured in pg/ml for each treatment for each day,
resulting in 6 cytokine profiles.
All procedures incorporated in the studies were reviewed and approved by the
University of Texas Medical School. The investigation was guided by the Veterinarian
Director of the Animal Resource Facility and associates with regard to handling,
analgesics and euthanasia for these studies. The Animal Resource Facility is fully
accredited by the American Association for the Accreditation of Laboratory Animal Care
for the use of warm-blooded animals in research, training or other activities sponsored by
grants, awards or contracts.
In silico. The Pathway Semantics Algorithm used the mouse (Mus musculus)
cytokine data for a node analysis of the biological pathways evoked by the treatments of
PBS or CFA/I at two time points: day 7 and day 14. There was insufficient data for day
28 at the time of the PSA analysis. Each mouse cytokine was identified by its gene name.
Its UNIPROT Accession ID was used to obtain the molecular weight, which was adjusted
by the number of receptors required for signal transduction. See Table 5-1. Method
details for node analysis have been previously detailed in Chapter 2.
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Table 5-1: Cytokines measured in Hemophilia A study

G-CSF
GM-CSF
IFN-γ
IL-1a
IL-1b
IL-2
IL-4
IL-5
IL-6
IL-7
IL-9
IL-10
IL-12 p35
IL-13
IL-15
IL-17
IP-10
KC
MCP-1
MCP-1a
RANTES
TNF-α

Gene
Name

UNIPROT UNIPROT
Accession MW of the
ID
unprocessed
precursor

Csf3
Csf2
Ifng
Il1a
Il1b
Il2
Il4
Il5
Il6
Il7
Il9
Il10
Il12a
Il13
Il15
Ctla8
Cxcl10
Cxcl1
Ccl2
Ccl3
Ccl5
Tnf

P09920
P01587
P01580
P01582
P10749
P04351
P07750
P04401
P08505
P10168
P15247
P18893
P43431
P20109
P48346
Q62386
P17515
P12850
P10148
P10855
P30882
P06804

22,421
16,091
17,907
31,023
30,931
19,400
15,834
15,410
24,384
17,727
16,075
20,673
24,179
14,108
18,593
17,490
10,789
10,254
16,326
10,345
10,071
25,896

#
receptors
reqd for
signal

Weighted
value for
signal
transduction

1.0
1.0
2.0
1.0
1.0
1.0
1.0
2.0
1.0
1.0
1.0
2.0
2.0
1.0
1.0
2.0
1.0
1.0
1.0
1.0
1.0
3.0

22421
16091
35814
31023
30931
19400
15834
30820
24384
17727
16075
41346
48358
14108
18593
34980
10789
10254
16326
10345
10071
77688

divide
pg/ml
by__ to
get
pmol/L
22.4
16.1
35.8
31.0
30.9
19.4
15.8
30.8
24.4
17.7
16.1
41.3
48.4
14.1
18.6
35.0
10.8
10.3
16.3
10.3
10.1
77.7

22 mouse (Mus musculus) cytokines were measured in pg/ml. For pathway generation,
the median values of the Significance Sets were converted from pg/ml to a signaltransduction weighted pmol/L, which more accurately represented the signal strength.
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Step 1. Dimensionality Reduction. Statistical analysis was performed using the nonparametric Mann–Whitney–Wilcoxon (MWW) test (www.spss.com) to identify the
Significance Sets of molecules that differentiated the treatments on both days.
Step 2. Ingenuity Pathways Analysis (IPA) was used to find the likely neighboring
pathways molecules (Ingenuity® Systems, www.ingenuity.com). Although the inputs
were identified as mouse cytokines, the pathway generation algorithm was not limited by
species in order to include information from other species’ pathways that may not have
yet been discovered in mouse pathways.
Step 3. The IPA network diagrams were converted to temporal dependency matrices
(TDMs), one for each day and each treatment.
Step 4. The TDMs were compared to identify molecules that differentiated the
treatment of PBS or CFA/I.
Laboratory. Based on the PSA results, an immunoassay test would be performed on
mouse supernatant for at least one of the predicted molecules at one time point to validate
the PSA. The molecule(s) tested would depend on availability of the appropriate
laboratory kit(s) to Dr. Csencsits Smith.
Results
PSA identified the Significance Sets of measured cytokines that statistically differentiated
treatment of PBS (control) or CFA/I (p<.05, Mann Whitney) on day 7 as IL-5, RANTES
(CCL5), and TNF-α; on day 14 as G-CSF, IL-1a, IL-12, IL-13, IP-10 (CXCL10). The
median pmol/L values of the significant cytokines were entered into IPA for both
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treatments on both days to generate the most likely biological pathways. Four network
graphs were generated as shown in Figure 5-1, Figure 5-2, Figure 5-3, and Figure 5-4.
Figure 5-1: PBS Day 7

PBS is the “control” group. The molecules used for pathway generation are shaded:
IL-5, RANTES (CCL5), and TNF-α (TNF).
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Figure 5-2: CFA/I Day 7

CFA/I is the treatment by a novel tolerogenic protein. Both networks were generated
based on the same Significance Set of 3 molecules; however, very different networks
resulted due to the difference in the median values between treatments. In PBS, IL-5
had the lowest concentration whereas in CFA/I, TNF-α had the lowest concentration.
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Figure 5-3: PBS Day 14

The molecules used for pathway generation on day 14 were G-CSF, IL-1a, IL-12, IL13, IP-10 (CXCL10).
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Figure 5-4: CFA/I Day 14

There was little difference in the evoked networks for day 14 although both networks
were generated based on a larger Significance Set of 5 molecules than in day 7.
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Lists of the evoked molecules were assembled and counted; there were a total of 79
molecules. See Table 5-2.
Table 5-2: Evoked pathway molecule count
Day 7 & 14

Day 7

Day 14

PBS only

0

16

2

CFA/I only

0

16

2

PBS & CFA/I

9

10

24

79 molecules were evoked in the generated pathways for both outcomes on both days.
Of these, 36 appeared solely in one treatment.

The unique day 7 molecules are shown in Figure 5-5. Day 14 evoked LGAL59 and
PKCa/b for PBS and CCL6 & LBP under CFA/I treatment. Of particular interest on day 7
is the fact that PBS evokes defensin and TLR-2/TLR-4 and pro-inflammatory cytokines
of the IL-1 family. CFA/I evokes GT1b ganglioside that may decrease expression of
certain T-cell antigens; HLX, a transcription factor which may regulate the TH1 pathway,
and pro-inflammatory cytokines of the TNF family plus IL-25 (IL-17E), a cytokine
favoring the TH2-type immune response. By day 14, even though there were more
cytokines in the Significance Set than on day 7, the evoked networks only differed by two
molecules each, suggesting that the effects of the CFA/I treatment were time limited.
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Figure 5-5: Unique evoked pathway molecules on Day 7
PBS

Day 7

CFAI
Extracelluar Space
IGJ immunoglobulin J polypeptide
IL-25 (IL-17E) cytokine
KLK8 peptidase
TNF cytokine family (2)

Extracelluar Space
Defensin anti-microbial peptide (2)
IL-17B cytokine
IL-1 cytokine family (3)

Plasma Membrane
IGK immunoglobulin complex
GPR109B G-coupled protein receptor
HMMR motility receptor
VIPR2 peptide receptor
GD1b ganglioside signal modulator

Plasma Membrane
IgG transmembrane receptor (2)
GDNF transmembrane receptor
SLC12A6 transporter
tenascin N glycoprotein
TLR-2/TLR-4 toll-like receptor

Cytoplasm
IFI30 IFNG inducible enzyme
LRRC8C leucine repeat
PCP4 Purkinje cell protein
pleckstrin signaling protein

Cytoplasm
PEBP4 binding protein
RAB32 ras oncogene
Vacuolar proton ATPase

Other
peroxidase enzyme

Nucleus
HLX homeobox transcription regulator
KLF13 Kruppel-like transcription regulator

Because of the study hypothesis that T cells that secrete IL-17 have been linked with
the development of inflammatory disease, and the fact that IL-25 (IL-17E) – a cytokine
that favors a response opposite to that of IL-17 (IL-17A-F) – was evoked in the CFA/I
treatment on day 7, a validation test was run to compare the presence of IL-25 in the day
7 PBS and CFA/I supernatants.
Laboratory Method and Results. The immunoassay used was the R&D Systems
Mouse IL-17E (IL-25) Duoset ELISA kit (www.rndsystems.com/pdf/DY1399.pdf). Mouse
spleens were harvested at the indicated time, and lymphocytes isolated by mechanical
dissociation followed by water lysis to remove red blood cells. CD4+ T cells were
enriched using an EasySep Mouse CD4+ T cell enrichment kit
(www.stemcell.com/en/Products/Popular-Product-Lines/EasySep.aspx), and 1 x10^6 T
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cells/ml were cultured for 72 hours in RPMI-1640 media (ATCC) supplemented with
10% fetal calf serum (FCS, Atlanta Biologicals) in the presence of 3 U/ml recombinant
IL-2 (R&D Systems), 10 microg/ml FVIII (Kogenate FS, Bayer Pharmaceuticals), and 5
x 10^5/ml mitomycin c -treated feeder cells. Supernatants were harvested and stored at 80 degrees C before use in the ELISA.
Test results showed that the concentration of IL-25 was almost twice as high in the
CFA/I treatment as in the control PBS treatment. See Figure 5-6. This suggests that the
CFA/I treatment alters the immune signaling networks involved in the production and
prevention of anti-FVIII antibodies in a mouse model of hemophilia A.
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Figure 5-6: Validation of predicted IL-25 at day 7

8000!
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PBS!

CFA/I!

Using an ELISA immunoassay test for IL-25, the hypothesized predominance of IL25 in CFA/I was confirmed. Supernatant from cultures of splenocytes isolated from
untreated mice had 615 pg/ml of IL-25, similar to PBS on day 28.

Discussion
The Pathway Semantics Algorithm used cytokine data from a mouse model of the
disease hemophilia A to generate hypotheses about the progressive changes in the
immune response in anti-factor VIII antibody production. The experimental finding of the
predicted IL-25 molecule in the CFA/I treated group supports the study hypothesis that
CFA/I modulates the TH17 response. Although IL-25 (IL-17E) has significant sequence
homology to the IL-17 family(Lee et al., 2001), the molecule has very different
properties. The laboratory result that IL-25 decreased in both the PBS control and the
116

CFA/I treatment to a level close to cell culture controls by day 28 is consistent with the in
silico prediction that by day 14 CFA/I treatment effects would diminish. This is of
interest because, although there were more measured molecules that statistically
differentiated the treatments on day 14 than day 7, the evoked biological pathways on day
14 were almost identical. Based on this result, Dr. Csencsits Smith is planning
experiments on the timing for repeated CFA/I treatments to manage inhibitor production
because the peak response seemed to be at 7 days based on PSA.
Although these results are promising, there is much work to be done. In addition to
the considerations given in Chapter 2 about the Pathway Semantics Algorithm and its
reliance on external data, more laboratory validation is required. The presence of the one
predicted molecule that supports the study hypothesis is a beginning. What PSA brings is
the ability to use multi-cytokine panels of measured data to infer non-measured
molecules and interactions. For the Laboratory Scientist, the Pathway Semantics
Algorithm narrows the scope for exploration, thus reducing labor and costs associated
with lab research and potentially increasing the chance for novel discovery.
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Chapter 6 Conclusions and Suggestions for Future Research
Conclusions
Problem Statement. There is a need to connect bioassay data with pathway
information within specific biomedical contexts and to facilitate comparison of biological
pathways by time, outcome, and other stratifications. If these needs could be met, clinical
research could start utilizing the wealth of constantly updated pathway information on a
regular basis to generate baseline hypotheses for biological mechanisms, diagnosis,
prognosis and therapy.
Problem Assessment. Based on an extensive literature survey of computational
methods, there appears to be no generalizible, computable systems-level methods that
utilized spatiotemporal bioassay data to answer biomedical questions arising from
comparative analysis of biological pathways.
Research Goal. To address this need, the overarching aim of my dissertation project
was to develop a computationally tractable and mathematically sound algorithm that
enabled hypotheses generation about mechanisms of disease progression based on
quantitative and qualitative data from molecular and clinical sources.
Research Deliverable. I developed a novel method called the Pathway Semantics
Algorithm (PSA) that used matrix algebra to bridge the gap between biological and
clinical resources by improving the in silico identification of clinically useful hypotheses
about molecular patterns in disease progression. By framing biomedical questions within
a variety of matrix representations, PSA has the flexibility to analyze combined
quantitative and qualitative data over a wide range of stratifications. The resulting
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hypothetical answers can then move to in vitro and in vivo verification, research assay
optimization, clinical validation, and commercialization.
Application Findings. PSA identified differential temporal patterns of molecules
and molecular interactions in pathways evoked from measured cytokines in two disease
domains: shock / trauma and hemophilia A. The PSA results were validated by literature
and expert opinion, and also by experiment for hemophilia A. In the node analysis
described in Chapter 3, PSA identified and qualified 7 molecules in patterns across time
of the progression of multiple organ failure; of these, only 3 had been previously
associated with any shock / trauma syndrome. In the edge analysis described in Chapter
4, PSA identified different patterns of molecular interactions over time, outcomes, and
functional relationships in biological networks evoked during the progression of multiple
organ failure. Differences in the number of edges and unique edges for each stratification
were uncovered, showing the changing temporal patterns of the molecular functions of
activation, expression, inhibition, and transcription during the first 24 hours of trauma. In
addition, the novel matrix-based measure XTALK gave quantitative insights into
functional crosstalk in disease progression; the calculated results supported the existence
of the property of degeneracy in biological networks.
Algorithm Generalizations. PSA confirmed that computationally tractable matrix
algebra can integrate disparate quantitative and qualitative data for analysis over many
stratifications, even where data is sparse, such as in shock / trauma studies. In addition,
matrix algebra can facilitate computational time-based analysis that is usually thought of
as requiring differential equations or complex time series. By discretizing the data into
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time periods related to clinical measurement intervals, molecular data analysis can be
synchronized with the ongoing clinical care.
Application Generalizations. The Pathway Semantics Algorithm has been designed
as a general method that can be applicable to a wide range of translational biomedical
research. For example, stratifications over time, outcome, and interaction function were
demonstrated; others could be used, such as cell cycle or sub-cellular molecular location
if the data is available. The data requirements depend on the pathway generation software
used; for IPA, a wide variety of data types are supported.
Algorithm Limitations. The Pathway Semantics Algorithm is built from validated
quantitative components such as statistics and algebra, and the pathways come from
qualitative peer-reviewed biomedical literature through the Ingenuity Knowledge Base.
An extensive review of the literature, including the material in Chapter 2, showed that
there are no standard methods for connecting bioassay data with pathway information
within specific biomedical contexts or for comparing biological pathways over time and
other stratifications. In addition, there seem to be no standard approaches for assessment
of such methods and no established procedure to validate hypotheses derived from
pathway models. It can be argued is that the gold standard is verification of hypotheses in
vivo. Such an extended study is clearly beyond the scope of this research project. Instead,
an informal content validity assessment of PSA by literature and expert opinion has been
performed during a four-year period, during which time it has not been discredited;
summary details follow in the validation section. Recently, PSA was confirmed
experimentally in the hemophilia A study. Due to the network export limitations of the
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IPA software and the resulting extensive manual labor currently involved, PSA has yet to
be formally documented for estimates of reliability and validity(Higgins & Straub, 2006);
it is planned to do this once PSA is automated and application results updated.
Application Limitations. Although these results provide insights into potential
hypotheses that may be useful in disease progression, the quality of the PSA algorithm
depends on quality data from assays, literature and biological pathway databases as well
as the statistical and network algorithms used. Due to the small sample sizes in the
disease domains under study, it was not feasible to perform a cross-validation of the
results. In cross-validation, the input data is partitioned into training and test sets. The
results would be analyzed to see if different hypotheses arise(Gutierrez-Osuna, 2009; W.
Li, Arena, Sussman, & Mazumdar, 2003). In addition, the Pathway Semantics Algorithm
was not formally assessed for reliability through a test-retest procedure(Nunnally, 1978)
due to lack of automation; it is planned to do this in future applications.
The limitations of the PSA node analysis were detailed in chapters 3 and 4.
Summarizing, the results rely on:
•

Quality of the patient data and the assay method

•

Quantity of the patient data

•

Dimensionality reduction through Significance Sets

•

Choice of statistical analysis used to identify Significance Sets

•

Quality of the biological pathway knowledge base and the algorithm used to
evoke biological pathways based on assay measurements

•

Changing nature of the biological pathway knowledge base
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•

Biological scope of the generated network

•

Utility of the molecular patterns

•

Resource requirements to implement PSA

Additional limitations resulted from the edge analysis described in Chapter 4:
•

Age of pathway data

•

Incomplete pathway data

•

Linearity assumption

Validation of Algorithm and Application Results. The Pathway Semantics
Algorithm was first presented for public critique in 2007. Since then, PSA, its
applications and results have been informally reviewed and validated for content by
multi-domain experts at conferences in systems and computational biology, trauma and
critical care, operations research, pathology and numerical algebra. Presentations have
been as follows; two awards have been received:
Signaling Pathways in Multiple Organ Failure (Poster).
•

The Eighth International Conference on Systems Biology. October 1–6, 2007.

•

Research Day, University of Texas Health Science Center at Houston. October
19, 2007.

•

Rice University 2007 Computational Biology Symposium. December 8, 2007.

Temporal Analysis of Signaling Pathways in Multiple Organ Failure (Presentation).
•

7th International Conference on Complexity in Acute Illness/International Shock
Conference, Cologne, Germany, July 2008.
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•

7th International Conference on Pathways, Networks, and Systems Medicine;
Corfu, Greece. Aegean Conferences 2009.

•

NLM Informatics Training Conference 2009: Portland, OR June 2009.

Measurement Units May Impact Results of Pathway Analysis (Abstract)
•

Journal of Critical Care. 2007 International Conference on Complexity in Acute
Illness (ICCAI)]. 2007;22(4):342-3.

Measuring Crosstalk in Biological Pathways (Poster)
•

2009 Keck Center Annual Research Conference, Houston, TX, October 2009.

•

Research Day, University of Texas Health Science Center at Houston. November
20, 2009. (Poster Award: 2nd Place Student Clinical and Translational Research)

•

Annual Meeting of the Association of Clinical Scientists, San Antonio, TX May
2010 (Presentation).

•

NLM Informatics Training Conference 2010: Denver, CO June 2010.

•

Conference on Numerical Linear Algebra: Perturbation, Performance, and
Portability: Austin, TX July 19–20, 2010.

•

The Ninth International Conference on Complexity in Acute Illness. Atlanta, GA
September 10–12, 2010.

•

INFORMS Annual Meeting 2010: Austin, TX, Nov 7–10, 2010. (Finalist Student
Competition).

Uncovering Immune Signaling Networks Involved in Anti-FVIII Antibody Production
in a Mouse Model of Hemophilia A Via Computational Analysis. (Poster)
•

2010 Keck Center Annual Research Conference, Houston, TX, October 2010.
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Implications and Expected Contributions to Science. The use of matrix
representation and numerical algebra, as used in the Pathway Semantics Algorithm
(PSA), offers a way to computationally integrate and analyze qualitative and quantitative
approaches for improved hypothesis generation about disease progression. PSA identifies
and compares likely temporal molecular patterns in biological pathways derived from
patients’ data, an important benefit that supports personalized medicine and that may
reduce the costs of disease research by narrowing the scope towards more likely
hypotheses.
This dissertation research project advances science in two areas: informatics and
translational biomedicine. Informatics is advanced by the demonstration that Pathway
Semantics facilitates the integration of qualitative and quantitative data, and along with
statistical and mathematical processing, strengthens the information content upon which
hypotheses are generated. The methodology appears to be repeatable, generalizable,
scalable and extendable. Translational biomedicine is advanced because Pathway
Semantics is designed to overcome the knowledge barrier between the ability to measure
abundant quantitative molecular data and the ability to connect that data with qualitative
biological pathway mechanisms that evoke hypotheses of clinical and biological
significance.
Suggestions for Future Research
Algorithm. Additional software development is required to automate the Pathway
Semantics Algorithm for node and edge analysis in general. As a composite method, PSA
now relies on commercial software processing components for statistical analysis,
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algebraic calculations, and biological network generation. The first two are generally
available as open source links; however, network generation algorithms and pathway data
are usually proprietary. Current intellectual property restrictions by Ingenuity Systems
have required extensive workarounds to utilize the data in the Ingenuity Knowledge Base
in a manner acceptable under the license provisions and also useful for PSA; it is
expected that meetings with Ingenuity Systems will continue on how to resolve this.
Meanwhile, other sources of biological pathway data and network generators are under
review. Once PSA is automated, future enhancements include support of data
perturbation analysis combined with support for probabilistic scenarios. In perturbation,
or sensitivity, analysis, the input data is changed incrementally and the stability of the
output hypotheses is assessed(Geard, Willadsen, & Wiles, 2005). For probabilistic
scenarios, the generated hypotheses can be strengthened by Bayesian inference, a form of
inductive reasoning commonly used in medical decision-making to assess the value of a
diagnostic test(Sox, Blatt, Higgins, & Marton, 1988). As an example, instead of using
median cytokine values to generate representative signaling pathways, a researcher could
use 75% values and see how the evoked pathways change. Combined with a sensitivity
analysis of biological pathways evoked from bioassay data, PSA could then be used for
“rule-in”/”rule-out” guidelines for clinical interpretation of molecular signaling data.
Application. I plan to continue analysis of disease progression in shock /trauma with
re-runs of all cytokine data collected in the original study. This will update the generated
biological pathways with the latest research, and add additional patient data
measurements beyond the first 24 hours already studied. The hypothesis is that biological
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pathways evoked in the first 24 hours from trauma differ from those in later times due to
changes in systemic response. The hemophilia A study continues, with the intent of using
patients’ cytokine data as they become available.
In a very different way, I plan to apply PSA to analysis of cancer progression within
the context of molecular tumor profiling. In chronic conditions such as cancer, the time
course is slower and the focus is on the molecules within the signaling pathways in
tumors that may be targeted by drugs. Instead of time, the component molecules in the
signaling pathways need to be evaluated by their cellular location, such as cytoplasm or
nucleus, and their cell cycle phase to determine cellular dysfunctions. Measurements
from molecular tumor profiling (using MorphoproteomicSM analysis by
immunohistochemistry(Tan, 2008)) include expression of signaling molecules in
compartment locations and analytes relating to cell cycle phase. This approach is used for
patients with tumors that have no established protocol or that have not responded to
conventional therapy(Robert E. Brown, Lun, Prichard, Blasick, & Zhang, 2004). Here
there is a need for an analysis of signaling pathways in tumor profiles that compares
molecular expression across specific locations and cell cycle phase for a better
understanding of the pathways that differentiate cancers. This will assist in the choice of
therapy for hard-to-manage cases.
Summary
The fundamental contribution of this research project is the methodology called the
Pathway Semantics Algorithm (PSA) as one solution towards the goals of connecting
bioassay data with pathway information within specific biomedical contexts and
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facilitating comparison of biological pathways by time, outcome, and other stratifications
to further diagnosis, prognosis and treatment for disease progression. This is a novel
approach to meet the need for both hypothesis and data driven strategies for result
analysis and interpretation of clinically derived data(Ghazal, 2008); this work advances
both informatics and translational biomedicine.
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Biological Networks generated from IPA in September 2009 (based on 27 cytokines)
Graphic images were exported on January 17, 2010. Measured input molecules in
pink to red; the darker the color, the higher the concentration. Solid lines are direct
interactions; dotted lines, indirect interactions. Here line color has no meaning; it resulted
from merging several networks.
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Cpla2
MHC Class II

JAK

IL7
Interferon alpha
IgG

C1q

IL5

Pka

STAT5a/b
IKK (complex)
Nos

Ap1
Nfat (family)

Ige

IL13
IL1

ERK1/2
Rap1

LDL

VitaminD3-VDR-RXR

CXCL10

Akt

IFN Beta
Hsp70

P38 MAPK
CCL11

IL1RN

CSF2

CCL2

Ifn gamma
IL6

Mapk
Mek

Histone h4

Jnk
CCL4

Ras

PI3K
ERK

FAK

Cyclooxygenase

IL12 (complex)

IL10

IFNG

HLA-DR

IL8
Tlr

NFkB (complex)

Fibrinogen

CSF3
SAA@

RNA polymerase II

Tgf beta

Histone h3

Vegf
Mmp
PDGF BB
NfkB-RelA

KSR2

MAP2K1/2

G

TFF2

Egfr-Erbb2
DUOX1

© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-5 MOF hours 10-14

Networks 1,2 Merged 9

KIR2DS2
IG9

Mek

PDGF BB
G
Rap1

FAK

Mmp

IL1F9
CCL11

Vegf

Ras

Nfat (family)
MAP2K1/2

Ige

CCL2

NfkB-RelA

Mapk

Fibrinogen

ERK
Jnk
Tgf beta

CXCL10

CSF2

P38 MAPK

SAA@
C1q

Ap1

IL8
CSF3

LDL

NFkB (complex)

VitaminD3-VDR-RXR
CCL4

Akt

IL13

ERK1/2

IgG

PI3K

Cpla2

IL6
IFNG
Ifn gamma

Pka

IL1RN

IFN Beta

IL1

IL5

Tlr

Iga
IL10

HLA-DR

IKK (complex)

Histone h3
IL12 (complex)

STAT5a/b

Igm

Interferon alpha

IL7

Arginase

Nos

Histone h4
RNA polymerase II
Hsp70

MHC Class II

Cyclooxygenase
IL-2R

JAK

AIF1

Il12 receptor
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-6 NMOF hours 10-14

167

Networks 1,2,3 Merged 10

TMOD1
HIRA
PPARGC1B

HOXA10

TCF7L2 (includes EG:6934)

GC-GCR dimer

Hdac

Hat

MT1F
SAA@

CYP24A1

VitaminD3-VDR-RXR
IFI27

NCOA1

Histone h4

Il8r

RNA polymerase II

CREBBP
ESR1

IL32

hCG

KLF6

IFI6
CXCL10

Histone h3
CDKN1A

Hsp70

Mmp

Vegf

RARB

MHC CLASS I (family)
IL1RN

IFN Beta
LZTS1

NFkB (complex)

Calpain

Jnk

CIITA

lipoxin A4

Ras

Akt

Cyclooxygenase
Pka

NfkB1-RelA

CSF3
IL8

Ifn gamma
Nos

STAT5a/b

ERK1/2

PDGF BB

HLA-DR

Tgf beta

IFNG

TNF

MAP2K1/2

Mapk

Ap1

Interferon alphaIL12 (complex)

G

GPR56
IL10

Fcgr3

IL1

P38 MAPK

Tlr

MHC Class II

Mek

ERK

PI3K
CSF2

IgG

LDL
IL7

FAK

Nfat (family)

CCL2

Ige
Arginase

IKK (complex)
CCL4

TCR

IL9

PLA2

Rap1

Rac

Ikb
Il12 receptor

Igm
IL13

IL5

NfkB-RelA

STAT

Iga
Tnf receptor
CCL11

Collagen(s)

Cpla2

IL-2R

C1q

DDR2
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-7 MOF hours 14-18

Networks 1,2,3 Merged 11

Iga

NfkB-RelA

Igm
Arginase

C1q
IL13

Ige

Ikb

Cpla2

CCL11

LZTS1
Cyclooxygenase

CCL4

Rap1

SAA@

IL5

CSF3
PLA2

IL9

IgG

GPR56

MHC Class II

LDL

Nfat (family)

Fcgr3

CCL2
P38 MAPK

FAK

Nos

IL1
ERK1/2

Rac

Tnf receptor

TCR

MAP2K1/2

IL12 (complex)

IL10

CSF2
Jnk

Mek

IKK (complex)

Pka
Tlr

IL7

Ras

LGALS3BP
Akt

G

Collagen(s)

NFkB (complex)

ERK

ADCY5

HLA-DR

TNF
Ifn gamma Interferon alpha

IL8
PDGF BB

IL32

STAT5a/b

Mapk

hCG

Ap1

IFNG

IL-2R MHC CLASS I (family)
Il12 receptor

IFN Beta

PI3K
IL1RN
Talin

CDKN1A

Vegf

Il8r

Hsp70

STAT

CYP24A1
NCOA1

CXCL10

VitaminD3-VDR-RXR

Mmp

Calpain

CREBBP

HLA-G

Tgf beta
Histone h3
PTMA

CAMK4
Histone h4

ESR1

MMP11

IFI27

RNA polymerase II

Hat
HOXA10

TRIM21

DDR2
MT1F

Hdac

PPARGC1B

CAPN3
HIRA

POLR2F

TMOD1

© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-8 NMOF hours 14-18

168

Networks 1,2,3 Merged 12
IGFBP7

KIR2DS2

PTGER4
NOD1

GPR56
Cyclin E

hCG

Mek

Cyclin A

IL1F9

Fibrinogen

Rap1

MT1F

HIRA

Pld

Il8r

PDGF BB

MAP2K1/2
CD3

Akt

Hat

G-protein beta

CXCL10
Ras
CCL11

Histone h3

Hdac

ERK

CSF3

Rac

VitaminD3-VDR-RXR
Jnk
Hsp90

Vegf

NFkB (complex)

ST13

Calpain
SAA@

IL8

ERK1/2

Ap1
Pka

Histone h4

C5AR1

CCL2

Nfat (family)

TCR

CCL5

Mapk

FAK

G

MHC CLASS I (family)
Tlr

Ifn gamma

IFNG

TNF

IL6

P38 MAPK

IgG

PLA2

CCR3
LDL

HDAC9 (includes EG:9734)
CSF2

Hsp27

Hsp70

DNAJB7

PI3K
Collagen(s)

HLA-DR
IKK (complex)

STAT5a/b

IL10
Interferon alpha

IL1

IL1RN

CIITA

Mmp

C1q

Tgf beta

CCL4
IFI27

NfkB-RelA

IFN Beta
IL12 (complex)

Nos

Ikb

STAT

IL7

Timp

Cpla2

DDR2

RNA polymerase II

MHC Class II

IFI6

Tnf receptor
Cyclooxygenase

Iga

CTSS

IL-2R

Fcgr3

JAK

Il12 receptor
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-9 MOF hours 18-22

Networks 1,2,3 Merged 13

BRCA1
Cyclin E
Timp

AHR

GNAQ
FAK

C5AR1
PDGF BB
Hsp27
RNA polymerase II

ZAP70

Cyclin A

Cyclooxygenase

IGFBP7

G-protein beta

Vegf

Collagen(s)

ERK

DUSP1

KIR2DS2

Calpain

MAP2K1/2
Mapk

Ap1

Hsp90

Rac

Nos
STAT5a/b

PI3K
Jnk

Mmp

CD3

Ras

Tgf beta

Mek
Pld

G

STAT
NFkB (complex)

P38 MAPK

TCR

IL1

Fcgr3

ERK1/2

IL6

Pka

TNF
IL7
JAK

CCL5

LDL

IL10

IFN Beta

Fibrinogen

Nfat (family)

Il8r

CXCL10

Interferon alpha

IL16
HLA-DR

IL12 (complex)

PLA2
CCL2

CSF2
DPP4

IgG

CCR2

SAA@

Rap1

CCL4
Hdac

hCG

IL8

CSF3

IFNG

IL-2R

TNFSF11

MHC Class II

Ifn gamma
Tnf receptor

Il12 receptor

G alphai

Akt

Hsp70

Histone h4

Histone h3

Tlr

CCR3

IL1RN

Hat
CCL11

Cpla2
IKK (complex)

NfkB-RelA

MHC CLASS I (family)
C1q

Ikb

cholecalciferol
VitaminD3-VDR-RXR

Iga
DNAJB7
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-10 NMOF hours 18-22

169

Networks 1,2 Merged 14
Mmp
C1q

PLA2
Il8r
CCL11
IgG

Hsp27

IL-1R

Rac
Rap1

IL1RN
NfkB-RelA

Mapk

FAK

SAA@

PI3K

CCL2

Vegf
Mek
LDL

IL1

Calpain

Ras
P38 MAPK
ERK

Akt

KSR2

MAP2K1/2

STAT

TNF

NFkB (complex)

IL6
MHC Class II

PDGF BB

Jnk

ERK1/2

IFN Beta

Tgf beta

Fibrinogen

STAT5a/b

IL8

Tlr

hCG
Nfat (family)

Cyclooxygenase

CSF2

IFNG

Interferon alpha

CSF3

CXCL10
Cpla2

Ap1

MHC CLASS I (family)

IKK (complex)

IL12 (complex)

Nos

Hsp90

Hsp70

IG9

Histone h3

Ifn gamma

Hat
Cyclin A

HLA-DR
Histone h4
RNA polymerase II

VitaminD3-VDR-RXR
Cyclin E

Hdac

DNAJB7
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-11 MOF hours 22-24

Networks 1,2 Merged 1
Hat
Il8r

Mek
Rac

NfkB-RelA

Rap1

CCL11
Hdac

Histone h4
Vegf

hCG

CCL2
Nfat (family)

Ras

PDGF BB

Hsp27

Histone h3

MAP2K1/2

SAA@

Hsp90
ERK

PI3K

P38 MAPK
C1q
Jnk
Akt

IL8
FAK

CSF3

TNF

Mapk

PLA2

IL1RN
ERK1/2

IG9

Ap1

NFkB (complex)

IgG

IL6

LDL

TMEM158
IL1

STAT5a/b
CSF2
IL12 (complex)
Cyclin A

Mmp

Hsp70
Fibrinogen

IFNG

STAT

IFN Beta
Ifn gamma

CXCL10

Calpain

Interferon alpha

Tgf beta

MHC CLASS I (family)
Nos
IKK (complex)

Tlr

Cpla2

RNA polymerase II

VitaminD3-VDR-RXR
MHC Class II

HLA-DR
Cyclooxygenase
AIM2

Cyclin E

DNAJB7
© 2000-2010 Ingenuity Systems, Inc. All rights reserved.

3-12 NMOF hours 22-24

170

Chapter 4

Biological Networks generated from IPA in July 2007 (based on 11 cytokines)
Graphic images were exported in January, 2011. Measured input molecules in pink
to red; the darker the color, the higher the concentration. Solid lines are direct
interactions; dotted lines, indirect interactions. Here, orange lines highlight the
interactions involved in the functional relationship under examination, such as activation.
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4-4 NMOF hours 6-10,
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4-5 MOF hours 6-10, Inhibition

NONE

4-6 NMOF hours 6-10, Inhibition
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4-7 MOF hours 6-10,
Transcription

NONE

4-8 NMOF hours 6-10,
Transcription
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Activation
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4-11 MOF hours 10-14,

Expression
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4-12 NMOF hours 10-14,

Expression
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4-13 MOF hours 10-14,

Inhibition
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4-14 NMOF hours 10-14,

Inhibition
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